Article:The relationship between sex hormones, the vaginal microbiome and immunity in HIV-1 susceptibility in women (6177003)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q58697026. Its title is The relationship between sex hormones, the vaginal microbiome and immunity in HIV-1 susceptibility in women and the publication date was 2018-08-28. The initial author is Jocelyn M. Wessels.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Disease Models & Mechanisms

The relationship between sex hormones, the vaginal microbiome and immunity in HIV-1 susceptibility in women

  • Jocelyn M. Wessels
  • Allison M. Felker
  • Haley A. Dupont
  • Charu Kaushic

[1]Hamilton, Ontario L8S 4L8

[2]Department of Pathology and Molecular Medicine

Publication date (ppub): 9/2018

Publication date (epub): 8/2018

Publication date (pmc-release): 8/2018

Abstract

ABSTRACT

The role of sex hormones in regulating immune responses in the female genital tract has been recognized for decades. More recently, it has become increasingly clear that sex hormones regulate susceptibility to sexually transmitted infections through direct and indirect mechanisms involving inflammation and immune responses. The reproductive cycle can influence simian/human immunodeficiency virus (SHIV) infections in primates and HIV-1 infection in ex vivo cervical tissues from women. Exogenous hormones, such as those found in hormonal contraceptives, have come under intense scrutiny because of the increased susceptibility to sexually transmitted infections seen in women using medroxyprogesterone acetate, a synthetic progestin-based contraceptive. Recent meta-analyses concluded that medroxyprogesterone acetate enhanced HIV-1 susceptibility in women by 40%. In contrast, estradiol-containing hormonal contraceptives were not associated with increased susceptibility and some studies reported a protective effect of estrogen on HIV/SIV infection, although the underlying mechanisms remain incompletely understood. Recent studies describe a key role for the vaginal microbiota in determining susceptibility to sexually transmitted infections, including HIV-1. While Lactobacillus spp.-dominated vaginal microbiota is associated with decreased susceptibility, complex microbiota, such as those seen in bacterial vaginosis, correlates with increased susceptibility to HIV-1. Interestingly, sex hormones are inherently linked to microbiota regulation in the vaginal tract. Estrogen has been postulated to play a key role in establishing a Lactobacillus-dominated microenvironment, whereas medroxyprogesterone acetate is linked to hypo-estrogenic effects. The aim of this Review is to contribute to a better understanding of the sex-hormone–microbiome–immunity axis, which can provide key information on the determinants of HIV-1 susceptibility in the female genital tract and, consequently, inform HIV-1 prevention strategies.

Precis

Summary: A better understanding of the sex-hormone–microbiome–immunity axis can provide key information about the determinants of HIV-1 susceptibility in the female genital tract and consequently inform HIV-1 prevention strategies.

Paper

Introduction

Clinical and experimental evidence indicates that many sexually transmitted infections (STIs) are more prevalent in women than men ([87]). The probability of human immunodeficiency virus (HIV) transmission via the female genital tract (FGT) is approximately 1.5- to 5-times greater than via the male genital tract (1 in 2000 to 1 in 200 in females versus 1 in 3000 to 1 in 700 in males) ([78]). There are both socio-economic and biological reasons why women may be more susceptible to STIs, including HIV-1, than men. The biological factors that could influence the outcome of pathogen exposure in the FGT include its large surface area, the alterations in physiology of reproductive tract tissues during different phases of the menstrual cycle, the influence of sex hormones on mucosal immune defense, the use of hormonal contraceptives and the effect of the indigenous microbiota (see Box 1 for a glossary of terms). In this Review, we highlight the mechanisms by which sex steroid hormones, including hormonal contraceptives, might impact the risk of HIV-1 susceptibility in women. This is an important and timely topic, given that approximately 40% of HIV-1 infections occur in the FGT and that women using the progestin-based injectable contraceptive depot-medroxyprogesterone acetate (DMPA) are 40% more likely to acquire HIV-1 than women not using hormonal contraceptives ([132]). The relevance of this area to public health is emphasized by the fact that more than 8 million women in sub-Saharan Africa, where HIV-1 is endemic, use DMPA as their main form of contraception ([143]).

Box. 1. Glossary

16S rRNA gene sequencing: an untargeted method to identify the bacterial taxa present in a microbiota. Typically, a variable region within the 16S ribosomal RNA (rRNA) gene that is unique to each taxa and codes for a component of the bacterial ribosome is amplified by PCR and sequenced.

Alpha-diversity: a term used in ecology to describe differences in species within a site, on a ‘local’ scale. In the context of this article, we are referring to the unique diversity of bacterial species found in the vaginal microbiota of each woman in our study.

Amsel criteria: a method to diagnose bacterial vaginosis (BV). Diagnosed by the presence of at least three of four clinical symptoms [thin/white/yellow vaginal discharge, clue cells (vaginal epithelial cells that appear stippled owing to being covered with bacteria) on microscopy, vaginal pH>4.5, fishy odor following addition of potassium hydroxide]. The Amsel criteria distinguish nonspecific vaginitis (BV) from other forms of vaginitis and from normal findings, as defined in [7].

Antimicrobial peptides (AMPs): part of the innate immune response for host defense, found in all classes of life.

Cervical transformation zone: the area of the cervix where the columnar epithelial cells lining the endocervix change into the squamous epithelial cells lining the ectocervix; an area thought to be particularly prone to HIV-1 acquisition.

Commensal: an organism living in relationship with another without harming or benefitting the host organism.

Defensins: small proteins found in vertebrates and invertebrates that function as antimicrobial host defense peptides.

Dysbiosis: a microbial imbalance.

Estradiol(E2)-based hormone replacement therapy (HRT): treatment with natural or synthetic estrogens alone or in combination with progestins, typically aimed at alleviating the symptoms of menopause, or preventing osteoporosis.

Ectocervix: the outer portion of the cervix that is located within the vaginal tract and lined by squamous epithelial cells.

Elafin: a defensin (antimicrobial peptide) with antibacterial activity against bacterial and fungal pathogens. Also known as Trappin-2.

HIV-1 gp120: a glycoprotein found on the exposed surface of the HIV-1 envelope.

Lactoferrin: a defensin (antimicrobial peptide) that also binds iron.

Lysozyme: a defensin (antimicrobial protein) that enzymatically cleaves and thus damages the components of the cell wall of Gram-positive bacteria.

Microbiota: a consortium of bacteria residing in and on multicellular organisms, including plants and animals.

Mucins: heavily glycosylated proteins (glycoproteins) produced by epithelial cells in most animals. They are a constituent of vaginal mucus.

NOD-like receptors: intracellular sensors of pathogen-associated molecular patterns (PAMPs). A type of pattern recognition receptor (PRR).

Pattern recognition receptors (PRRs): part of the innate immune system, these protein sensors detect pathogen-associated molecular patterns (PAMPs) and induce an innate response in the host.

RANTES (also known as CCL5): stands for ‘regulated on activation, normal T cell expressed and secreted’. A chemotactic protein (chemokine) that recruits T cells, eosinophils and basophils, or other cells with cognate receptors.

Seroconversion: the point at which a specific antibody has developed and become detectable in the peripheral blood (i.e. antibodies against HIV-1 indicate that seroconversion has occurred).

Seronegative: a negative result in a blood test for antibodies against a certain virus or condition (i.e. HIV-1 or rheumatoid arthritis).

Toll-like receptors (TLRs): intra- or extracellular proteins that recognize microbes and nucleic acids, and participate in the innate immune response. A type of pattern recognition receptor (PRR).

The female genital tract

The lower FGT, the vaginal tract and ectocervix (Box 1), is lined with epithelial cells covered by mucus and colonized by bacteria. It is the first location encountered by HIV-1 during heterosexual intercourse with an infected male partner. The lower FGT provides a protective physical and immunological mucosal barrier. Acting as a structural support beneath the epithelium is a dense layer of stromal fibroblasts, in which a diverse population of leukocytes reside ([183]). As HIV-1 preferentially infects CD4+ leukocytes [T cells, macrophages and dendritic cells (DCs)] residing in the stroma, the vaginal mucus and epithelial barrier serve in part to impede viral access to target cells ([133]). In order for HIV-1 transmission to occur, infectious virions must transverse the protective physical and immunological barriers of the FGT and infect target cells located in the stroma. While the exact mechanisms by which HIV-1 accesses target cells remain incompletely understood, this Review will focus on several factors known to influence HIV-1 susceptibility and acquisition in the FGT.

The lower FGT is lined with multi-layered squamous epithelial cells, and tight junctions linking these cells are mainly restricted to its basal layers. The epithelium in the lower FGT undergoes continuous differentiation, resulting in a mitotically active basal layer and a terminally differentiated superficial layer comprising cornified epithelial cells, which aid in preventing infection by certain pathogens, including HIV-1 ([10]). Aside from acting as a physical barrier, the vaginal epithelial cells also secrete mucins (Box 1) into the vaginal lumen. These form a hydrophobic layer of mucus that traps pathogens and prevents access to the underlying epithelial cells ([92]; [136]; [156]). In addition to mucins, the vaginal mucus contains other host defense molecules, including antimicrobial peptides (AMPs; Box 1) and complement system components, which can directly bind to and eliminate pathogens, impeding access to the vaginal epithelium ([17]; [136]). These protective features can effectively dampen HIV-1 motility in human cervicovaginal mucus and enhance vaginal barrier function ([156]). Colonizing the vaginal epithelium is an indigenous microbial community that can influence the physiology and immune function of the FGT ([35]; [99]). The resident vaginal microbiota (VMB) exists in a mutualistic relationship with the female host and also participates in preventing vaginal infection by a variety of pathogens. Notably, disruption of the VMB is associated with an increased risk of STIs, including HIV-1 ([14]). The impact of the VMB on inflammation and susceptibility to HIV-1 is an emerging area of interest and will be discussed in more detail below.

The upper FGT consists of the endocervix, uterus (endometrium), fallopian tubes and ovaries. It is lined by a single layer of epithelial cells linked by tight junctions that provide physical protection. It was originally believed that the upper FGT was sterile. However, like the vaginal tract, the upper FGT is colonized by bacteria ([32]; [40]; [73]; [112]; [113]). Several studies have reported significant correlation in microbial community members across the FGT, but their relative proportions vary ([32]; [176]; [177]). Furthermore, the quantity of bacteria found on the endometrial surface are 2-4 log orders of magnitude lower than those found in the vaginal tract ([32]; [112]), and lactobacilli typically represent a large fraction of the endometrial microbiota ([54]; [112]; [114]; [177]). However, studies also identified many low-abundance genera ([114]; [171]). Similar to the VMB, the endometrial microbiota may be able to modulate inflammation. In vitro co-cultures of endometrial epithelial cells with pathogenic bacteria (Neisseria gonorrhoeae) induced proinflammatory mediators ([33]), whereas other bacteria typically found in the reproductive microbiotas (Lactobacillus crispatus, Gardnerella vaginalis) did not ([94]). This suggests that the endometrial microbiota may be able to modulate endometrial inflammation in the host. HIV-1 infection can occur in the upper FGT, although the exact mechanism is unclear. HIV-1 has been shown to induce innate inflammation that can disrupt the mucosal barrier in the upper FGT ([118]), to transcytose across the endometrial epithelial barrier ([49]; [79]) and to infect ovarian tissue cells in vitro ([155]), which could influence initiation of HIV-1 infection. Simian immunodeficiency virus (SIV), the primate analog of HIV, can also rapidly access and infect target cells throughout the lower and upper FGT ([161]). A number of other reviews have focused on the possible mechanisms of HIV-1 infection in the upper FGT ([38]; [48]; [75]; [95]; [122]; [186]). In this Review, we discuss the recent information that is relevant to HIV-1 transmission in the lower FGT (ectocervix and vagina), which make up the major surface area exposed to HIV-1-infected semen during heterosexual intercourse.

Although one of the main functions of the immune system in the FGT is to protect against an array of pathogens, it must concurrently allow for the main reproductive functions of the FGT, including supporting sperm migration, oocyte fertilization and embryo implantation. To balance these unique requirements, the FGT is precisely regulated by the sex steroid hormones estradiol (E2) and progesterone, which are cyclically produced by the ovaries throughout the menstrual cycle during the reproductive years in women ([139]; [183], [186]). Both fluctuating endogenous sex hormones and hormonal contraceptives can alter the components of the FGT defensive barriers, including mucus viscosity, epithelial barrier thickness, immune cell frequency and resident vaginal microbes ([172]; [186]). For example, the amount and composition of the vaginal mucus varies with the menstrual cycle, hormonal contraceptive use, and hormone dampening at menopause ([30]; [65]; [157]). During ovulation, under the influence of estradiol, the vaginal mucus is thin with low viscosity, which facilitates sperm movement. Conversely, during the progesterone-high luteal phase of the menstrual cycle, the vaginal mucus is thick and viscous, which impedes the movement of particulates from the lower to the upper FGT. Together, the carefully regulated fluctuations of these physicochemical features are necessary to promote both reproductive success and a robust defensive barrier in the FGT. As these first lines of defense are heavily influenced by both hormones and microbiota composition, their dynamic interactions can substantially influence HIV-1 susceptibility in women, and will be discussed in detail below.

Immunity in the lower female genital tract

In the lower FGT, epithelial cells, stromal fibroblasts and leukocytes interact with each other, with the sex hormones and with the VMB to induce the two arms of the immune response: innate and adaptive immunity ([48]; [122]; [190]). In addition to acting as a physical barrier against pathogens, the epithelial cells of the lower FGT modulate leukocyte function by producing cytokines and chemokines, which induce leukocyte differentiation and mediate inflammatory processes ([43]). Epithelial cells in both the upper and lower FGT (Fig. 1) possess a wide array of pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (Box 1), which recognize and respond to pathogens through conserved pathogen-associated molecular patterns (PAMPs) expressed by microorganisms ([63]; [74]; [131]). However, PRRs appear to be differentially regulated and expressed by epithelial cells depending on their location within the FGT, with a limited expression of PRRs in the lower compared to the upper FGT ([63]; [72]; [131]). Pathogen recognition by PRRs induces intracellular signaling and activates the transcription factor NF-κB, resulting in the production of AMPs and pro-inflammatory cytokines ([50]; [122]). For instance, primary epithelial cells isolated from the human vagina and ectocervix can induce NF-κB signaling upon activation of the TLR pathway to produce pro-inflammatory cytokines, including interleukin 6 (IL-6), IL-8, tumor necrosis factor α (TNF-α), macrophage inflammatory protein 1α (MIP-1α) and MIP-1β ([52], [50]). Indeed, epithelial cells from both the upper and lower FGT have been reported to activate signaling pathways following pathogen exposure ([47]; [118], [117]). Furthermore, our group recently demonstrated that HIV-1 gp120 (Box 1) signaling through TLR2 induced interferon β (IFN-β) production in genital epithelial cells, which had an anti-inflammatory activity and protected the function of the epithelial barrier ([120]). In addition to inflammatory cytokines, cervicovaginal epithelial cells are known to produce AMPs, including defensins (Box 1), secretory leukocyte protease inhibitor (SLPI), lysozyme, lactoferrin and elafin (Box 1) ([122]; [183]). In vitro cultures of ectocervical epithelial cells secrete AMPs, including SLPI1, Trappin-2/elafin and human beta defensin 2 (HBD-2) ([184]), which are known to have anti-HIV-1 activity ([2]; [62]; [105]; [163]). Taken together, the epithelial cells of the lower FGT contribute to recognition of and defense against pathogens in part via their induction of inflammation and AMPs. Fig. 1.

Anatomy and immunological components of the female genital tract. The female genital tract (FGT) can be separated into the upper (ovary, fallopian tube, uterus/endometrium and endocervix) and lower (ectocervix and vagina) tract. The vaginal epithelium has many innate immune protection mechanisms, such as tight junctions, antimicrobial peptides (AMPs) and mucus, in order to neutralize, trap and prevent entry of potential pathogens. The vaginal lumen is colonized by commensal bacteria, mainly lactobacilli, which help to maintain a low pH. Furthermore, immune cells such as γδ T cells, dendritic cells (DCs) and macrophages are present beneath and between the vaginal epithelial cell layer to survey the local environment for danger. The abrupt transition from keratinized squamous epithelial cells of the ectocervix to single columnar epithelial cells of the endocervix represents the transformation zone; this site has an abundance of HIV-1 target cells and has been proposed to be one of the major sites for infections. The presence of lymphoid aggregates in the endometrial tissue suggests that this is an inductive site for cell-mediated immunity. Lymphoid aggregates found beneath the endometrium are composed of B cells in the inner core surrounded by CD8+ CD4− T cells and an outer layer of macrophages. A scatter of CD56+ natural killer (NK) cells and CD4+ T cells could be found in between lymphoid aggregates. It was originally believed that the upper FGT was sterile; however, like the vaginal tract, the upper FGT is colonized by bacteria, including lactobacilli. Figure modified and reprinted with permission from [122]. TLR, Toll-like receptor.

Residing in the lower FGT are numerous, dynamic leukocyte populations that contribute to humoral and cellular immunity. Leukocytes constitute 6-20% of all cells in the FGT ([122]; [186]), and possess unique characteristics that differentiate them from other tissue resident and peripheral leukocytes. For instance, flow cytometry measurements showed that primary vaginal macrophages were more susceptible to HIV-1 infection in vitro than gastrointestinal macrophages ([153]). Leukocytes of the FGT are preferentially distributed in immunological microenvironments depending on their function within the FGT. In the cervical transformation zone (Box 1), T cells and antigen-presenting cells (APCs), including many CD14+ macrophages and DCs, are particularly abundant ([135]; [167]). The presence of CD4+CCR5+ T cells, which are the primary targets for HIV-1 infection, renders the transformation zone particularly vulnerable ([42]; [90]; [135]; [167]; [172]). DCs, including intra-epithelial CD1a+ Langerhans cells, are present in the squamous epithelial cell layers of the ectocervix and vagina ([135]). These cells can be infected by and are thought to facilitate HIV-1 transfer across epithelial cells of the lower FGT ([15]; [165]). Further, cervical DCs express DC-SIGN, a C-type lectin receptor and adhesion molecule that also acts as an HIV-1 receptor. The presence of DC-SIGN on DCs has been implicated in enhanced transmission of HIV-1 to T cells ([59]; [58]). Thus, while T cells are the main targets for HIV-1, macrophages and DCs can also be infected and therefore directly and indirectly affect HIV-1 susceptibility in women.

Most T cells in the lower FGT reside near the basal epithelial cell layer at the stromal cell interface; however, a large T-cell population also resides in the ectocervical and vaginal epithelium as intra-epithelial lymphocytes ([135]). Although CD8+ T cells are slightly more abundant than CD4+ T cells ([167]), the CD4+ T cells represent a greater number of the intra-epithelial lymphocytes in the ectocervix ([135]). Interestingly, the number of vaginal intra-epithelial CD4+ and CD8+ T cells, as well as CD1a+ DCs, is elevated in women with inflammation of the FGT ([135]), and CD8+ T cells of the vagina and cervix possess cytolytic activity ([135]; [179]). In recent years, T-helper 17 (Th17) cells have been identified as preferential targets for HIV-1 in the human cervix ([34]; [103], [104]). These CD4+IL17A+ cells co-express the HIV-1 co-receptor CCR5 and mucosal integrin α4β7, which is known to bind HIV-1 gp120 and enhance viral dissemination ([34]). Importantly, this Th17 population is almost completely depleted in HIV-1+ women, indicating its potential as a key target for HIV-1 transmission ([103]). Thus, given their abundance, susceptibility and location, CD4+ T and Th17 cells are considered the major targets of HIV-1 in the lower FGT. Hence, the factors influencing the number and activation of these cells can greatly impact HIV-1 susceptibility.

Although B cells are a key cellular component of the adaptive immune system, they are not present in large numbers in the lower FGT. Resident immunoglobulin A (IgA)-expressing plasma cells have been described in the cervix, especially in the endocervix ([122]). In fact, studies examining antibody responses in the FGT have identified modest IgA and IgG responses against viral infections, including HIV-1, in cervical secretions ([146]). Unlike in other mucosal sites, the dominant antibody isoform produced during the adaptive immune response in the FGT is IgG rather than IgA ([97]; [146]), yet both isoforms can transfer across the genital epithelium. In the case of IgG, the neonatal Fc receptor (FcRN) on genital epithelial cells facilitates transfer of IgG to the lumen to confer protection against vaginal infections ([97]). Even though relatively little is known about the role of B cells and antibodies in the FGT, in theory they have the potential to contribute to adaptive immunity and offer an additional layer of protection against HIV-1. An overall summary of the general changes in immunity over the menstrual cycle are highlighted in Fig. 2. Fig. 2.

Changes in lower female genital tract immunity and HIV-1 susceptibility under endogenous and exogenous sex hormones. The endogenous levels of female sex hormones (estradiol and progesterone) vary throughout the 28-day menstrual cycle in women. Estradiol dominates the follicular phase and reaches peak levels just prior to ovulation, which occurs around day 14. Post-ovulation, estradiol levels decline as progesterone levels rise towards the mid-luteal phase. The progestin-based injectable contraceptive depot-medroxyprogesterone acetate (DMPA) is administered every 3 months. Levels of this progestin, a synthetic progesterone, are highest in serum within the first 20 days of administration. Women on DMPA have consistently lower estradiol levels than normally cycling women ([70]). A summary of the putative effects of hormones and hormonal contraceptives on female genital tract (FGT) immunity as presented in this Review are summarized as shown. Overall, while estradiol appears to promote factors related to decreased HIV-1 susceptibility, alterations in immunity during periods of high progesterone or DMPA use are associated with increased HIV-1 susceptibility. DCs, dendritic cells; Ig, immunoglobulin; Th2, T-helper type 2 cells; Th17, T-helper 17 cells.

Effect of endogenous and exogenous sex steroid hormones on immunity in the FGT

It is well documented that the endogenous female sex steroid hormones estradiol and progesterone, and their synthetic analogs, including those found in hormonal contraceptives, regulate immunity in the FGT. Other reviews provide a detailed account of this immunoregulatory influence on immune cell phenotype and function ([38]; [86]; [122]; [172]; [185]). In this article, we focus on the effect of endogenous and exogenous hormones in modulating key target cell populations, and thus HIV-1 susceptibility, in the lower FGT.

Although alterations in immune cell populations occur in endometrial tissues of the upper FGT ([122]), flow cytometry analyses did not confirm major fluctuations in their location or abundance in the lower FGT between the phases of the menstrual cycle or between pre- and post-menopausal women ([66]; [135]; [167]). High levels of cytolytic activity were observed in CD3+ T cells isolated from the cervix and vagina, but this was independent of menstrual cycle stage. Women of reproductive age have significantly more CD4+, CD8+ and B cells in their ectocervix than in the endocervix ([167]). Further, the ectocervix has also been shown to contain higher numbers of CD4+ T cells in women with vaginal/cervical inflammation ([135]; [180]). However, other phenotypic and functional changes can occur within specific immune cell populations in response to sex hormones. For example, cellular proliferation and secretion of Th1-type cytokines was impaired in peripheral blood CD4+ and CD8+ T cells treated with progesterone, instead favoring the development of Th2-type cytokine-producing T cells ([39]; [130]). Progesterone treatment of murine bone-marrow-derived DCs resulted in inhibited differentiation of DCs, leading to increased antigen uptake and decreased production of inflammatory cytokines, whereas opposing effects were observed after estradiol treatment ([188]). Furthermore, immunohistochemistry of vaginal biopsies from women of reproductive age who received intravaginal delivery of exogenous progesterone showed increased numbers of CD1a+ Langerhans cells ([181]), which are implicated in HIV-1 transfer across epithelial cell barriers ([15]; [165]). In addition to affecting HIV-1 target (CD4+HLA-DR+CD38+CCR5+) cells, progesterone also alters humoral immunity, as IgG and IgA titers in the cervical secretions were diminished in the luteal compared to the follicular phase of the menstrual cycle ([149]), and immunoglobulin levels peaked just prior to ovulation, when estradiol levels were high ([55]; [91]). Similarly, progesterone is elevated in the luteal phase and is correlated with increased secretion of AMPs including defensins, trappin-2/elafin and SLPI in cervicovaginal lavage ([38]; [62]). Collectively, these results help illuminate the possible mechanisms by which progesterone might modulate immunity in the FGT and relate to HIV-1 susceptibility, which is greater in women in the progesterone-high luteal phase of the menstrual cycle ([148]; [182]).

Although progesterone has been linked to increased HIV-1 susceptibility, estradiol can also impact immunity in the FGT. Depending on its concentration, estradiol can exert pro- or anti-inflammatory responses and differentially affect immune function ([162]). Both sex steroid hormones can also affect PRR expression throughout the FGT. Estradiol is able to modulate the downstream signaling of PRRs and pro-inflammatory receptors, as well as regulate NF-κB function ([44]; [61]; [150]). For instance, estradiol inhibits the mRNA expression of inflammatory cytokines IL-1α, Il-6, IL-8 and TNF-α in vaginal epithelial cell lines ([175]). Similarly, in vitro studies of human ectocervical epithelial cells treated with estradiol showed decreased production of IL-1β and IFN-γ ([147]), and vaginal cells captured using a menstrual cup and treated with estradiol had decreased secretion of the AMPs HBD2 and elafin ([128]). In primary murine microglia and RAW 264.7 cell macrophage populations, treatment with estradiol induced anti-inflammatory activity by inhibiting intracellular transport of NF-κB family members to the nucleus ([61]), while exogenous estradiol treatment of peripheral blood macrophages and CD4+ T cells reduced HIV-1 viral entry through a CCR5-independent pathway ([141]). Estradiol can also inhibit in vitro Th17 differentiation in mouse splenocytes ([31]), and mouse models of viral infection have demonstrated that estradiol can enhance the response of Th17 cells and Th1-type responses following viral exposure ([11]). Taken together, these results suggest that estradiol typically maintains an anti-inflammatory immune environment that helps reduce susceptibility to infections while still maintaining the ability to mount an inflammatory, anti-viral response when necessary.

In addition to the impact of endogenous sex steroid hormones on immunity in the FGT, exogenous hormones, such as those commonly found in hormonal contraceptives, can also affect immunity in the FGT. This is an area of active research, particularly because the progestin-based injectable contraceptive DMPA is linked to increased HIV-1 susceptibility ([70]; [85]; [115]; [132]). In a recent study, women on DMPA had greater expression of RANTES (also known as CCL5; Box 1) and decreased expression of the AMP BD2, which were implicated in HIV-1 seroconversion (Box 1) ([52]). Furthermore, an increased frequency of the HIV-1 target CCR5+CD4+ T cells was also observed in cervical cell populations isolated from women using injectable progestin-only contraceptives, including DMPA ([26]; [29]). In contrast, women using a progestin-based intrauterine device (IUD) had reduced expression of the HIV-1 co-receptor CCR5 on cervical T cells ([4]). However, increased numbers of HIV-1 target cells are not consistently observed in women on DMPA ([106]; [111]). MPA, the active component in DMPA, was also shown to inhibit the activation of T cells and peripheral dendritic cells (pDCs) in response to T-cell-receptor- and TLR-mediated activation at physiological concentrations in peripheral blood mononuclear cells derived from pre-menopausal women ([82]). In other studies, MPA also impaired the expression of DC activation markers and affected their ability to promote T-cell proliferation ([137]). Recent transcriptomic studies from our group investigated the impact of sex hormones and MPA on the mRNA profile of primary endometrial epithelial cells and found that MPA significantly increased expression of inflammation-related genes ([187]). Taken together, MPA is thought to negatively impact immunity as it relates to HIV-1 susceptibility in the FGT, despite several studies reporting it to be immunosuppressive ([70]). The overall changes in immunity under the influence of DMPA are highlighted in Fig. 2.

Combined oral contraceptives (COCs), which contain analogs of both estradiol and progesterone, are generally thought to have protective effects against viral infection in the FGT, depending on their formulations and quantity of the analogs. For example, one study found higher levels of inflammatory cytokines, including IL-1β, IL-6 and IL-8, in women on COCs compared to women who were not using hormonal contraceptives ([52]). While T cells isolated from the cervical epithelium of women using COCs showed no difference in expression of activation markers or CXCR4 compared to women not on COCs, the number of T cells expressing CCR5 was higher in women on COCs ([134]). Conversely, multiple studies investigating immunoglobulins in cervical secretions revealed that women on COCs had higher IgG and IgA levels than naturally cycling women ([55]; [149]), suggesting that adaptive immunity might be stronger in the women on COCs. Thus, exogenous exposure to hormonal contraceptives impacts immunity in the lower FGT, in ways that may impact susceptibility to HIV-1 infection.

Factors affecting susceptibility to HIV-1 in women

To establish infection in the FGT, HIV-1 must first evade the previously discussed anatomical and biological barriers. Although these are effective, since the frequency of HIV-1 infection is approximately 1 in 200 to 1 in 2000 per act of unprotected receptive vaginal intercourse ([78]), several factors can influence susceptibility ([48]). Firstly, disruption of the vaginal epithelial barrier can enhance HIV-1 susceptibility in women. HIV-1 can penetrate the squamous epithelium of the lower FGT through simple diffusive percolation, and the depth of viral penetration significantly increases when the epithelial tight junctions are disrupted ([27]). Disruption of the vaginal epithelial barrier can occur during heterosexual intercourse as a result of microabrasions. These activate local inflammation and wound-healing processes, and promote infiltration of immune cells, which could ultimately amplify the population of HIV-1 target cells ([107]; [124]). In fact, women with disruptions of the genital epithelium are at the greatest risk of HIV-1 acquisition (hazard ratio of 4.30) compared to women without compromised epithelial barriers ([1]), further supporting the association between barrier disruption and HIV-1 acquisition. Alternatively, the epithelial barrier can be disrupted by HIV-1 and its gp120, which disrupt tight-junction proteins like ZO-1 and occludin in cultured primary upper FGT cells ([118], [119]). In vivo studies have also shown that differing hormonal and microbial compositions influence protease levels in the FGT, which may in turn impact the integrity of the vaginal epithelial barrier and influence HIV-1 susceptibility ([12]; [16]; [20]). Normally, the low pH of the vagina provides another layer of protection against pathogens. However, the alkaline pH of semen temporarily increases vaginal pH, and this can prevent HIV-1 from being neutralized by the normally acidic cervicovaginal mucus ([92]; [166]), thereby increasing the risk of infection. Therefore, mechanisms that breach the vaginal epithelial barrier or alter the pH can significantly increase the odds of HIV-1 successfully encountering its target cells.

There is also a strong epidemiological association between concurrent STIs and increased risk of HIV-1 acquisition; in meta-analyses, both human papillomavirus (HPV) and herpes simplex virus 2 (HSV-2) have been associated with a 2- to 3-fold increased risk of HIV-1 acquisition ([56]; [80]). While the precise mechanisms for these epidemiological associations remain unclear, research suggests that the augmented risk is due in part to increased inflammation in the FGT, as shown by higher inflammatory cytokines present in primary genital epithelial cells exposed to co-pathogens ([46]), which enhanced HIV-1 infection and replication in target cells. In support of this hypothesis, genital HSV-2 infection has been found to induce a pro-inflammatory profile characterized by increased numbers of HIV-1 target cells that can persist at mucosal sites of HSV-2 reactivation, which may explain in part why individuals with HSV-2 have increased HIV-1 susceptibility ([191]). In general, any state resulting in the activation of the immune system and/or the recruitment of immune cells, including HIV-1 target cells, may enhance the risk of HIV-1 susceptibility. In fact, a recent study found that the risk of HIV-1 acquisition was increased 3-fold in women with genital inflammation, as defined by elevated HIV-1 target-cell-recruiting chemokines and inflammatory cytokines ([102]). Conversely, reduced inflammation in the FGT was associated with protection from HIV-1. In a cohort of women who were highly exposed to HIV-1 yet remained seronegative (Box 1), dampened genital immunity was proposed to limit target cell availability and activation, and to maintain the protective vaginal barrier, thus decreasing the risk of HIV-1 infecting its target cell population ([93]). This relationship has also been demonstrated in vitro, where pre-treatment with curcumin, a potent anti-inflammatory agent, prevented the disruption of the mucosal barrier by maintaining ZO-1 and occludin when primary upper FGT cells were exposed to HIV-1 and gp120 ([49]). Although an inflammatory milieu is believed to be a primary contributor to HIV-1 susceptibility in women, the frequency of vaginal HIV-1 target cells was found to be the key predictor of HIV-1 susceptibility in a humanized mouse model of heterosexual transmission, independent of inflammatory cytokines ([123]). These results suggest that increased numbers of HIV-1 target cells are sufficient to increase susceptibility, even without enhanced pro-inflammatory cytokine production. However, the presence of inflammation significantly increases HIV-1 susceptibility.

As mentioned in the previous section, endogenous sex steroid hormones can modulate immunity in the FGT. Thus, in addition to the integrity of the vaginal barrier and inflammation, sex steroid hormones and, by extension, hormonal contraceptives, represent another factor that can modify susceptibility to HIV-1 in women. Generally, estradiol has been associated with protection against HIV-1, while progesterone and the synthetic progestin DMPA appear to increase risk ([16]; [115]; [148]). In fact, some studies have found significantly increased target T cells in women on DMPA ([26]; [29]). However, because this observation is not consistent ([106]; [111]), it cannot be the sole mechanism by which DMPA enhances susceptibility to HIV-1. Not only are sex hormones and hormonal contraceptives thought to manipulate local HIV-1 target cells, but recent studies have also implicated them in epithelial tissue remodeling, immune cell migration and microbiota composition, suggesting they can impact more than one of the factors that contribute to HIV-1 susceptibility ([5]; [111]; [187]).

A more recently established risk factor for HIV-1 that we highlight in this Review is the VMB. Disruption of the resident VMB can be linked to increased HIV-1 susceptibility, and is most notable in the case of bacterial vaginosis (BV). In fact, BV has been shown to increase the frequency of HIV-1 infection up to 60% ([14]). Although increased relative abundance of anaerobes and decreased numbers of lactobacilli are key features of BV, the mechanisms by which the VMB increases HIV-1 susceptibility remain largely unknown, but are speculated to relate to their control of vaginal inflammation. Although the etiology and bacterial species that initiate BV are widely debated, it has been proposed that BV might be a biofilm condition ([116]; [152]). It has been hypothesized that G. vaginalis, which can be present in the VMB of women without BV, can induce formation of a biofilm that includes other BV-associated bacteria ([152]). The BV biofilm adheres to the vaginal epithelium and produces cytotoxic substances ([116]), and may also impact local immune function and thus HIV-1 susceptibility. BV often recurs or is refractive to antibiotic treatment, perhaps due to persistence of the biofilm. It is however important to note that biofilms can be present in women without BV [as assessed by the Amsel criteria ([7]); Box 1] ([140]; [164]), and the effect of these biofilms on vaginal immunity is largely unknown. While many factors associated with increasing the risk of HIV-1 in women have been described, including disruption of the vaginal barrier, concurrent STIs, sex hormones/hormonal contraceptives and the VMB, HIV-1 infection is multifactorial and likely involves mechanisms that remain to be elucidated (Fig. 3). Fig. 3.

Factors affecting susceptibility to HIV-1 in women. There are many factors associated with an increased risk of HIV-1 in women, including disruption of the vaginal barrier, concurrent STIs, the sex hormones, hormonal contraceptives and the vaginal microbiota (VMB). However, the establishment of HIV-1 infection is multifactorial and likely involves mechanisms that remain to be elucidated. A word cloud was created using wordclouds.com to depict factors associated with increasing susceptibility to HIV-1 in women. The size of the text is proportional to the number of publications returned in PubMed (March 2018) when searching for HIV-1 and the corresponding factor. Factors returning 25-99 hits (i.e. hormonal contraceptives) are listed in the smallest font, followed by factors returning 100-499 hits (i.e. sex hormones), 500-999 hits (i.e. target cells), and the largest font represents factors with more than 1000 hits (i.e. inflammation).

Effects of the vaginal microbiota on inflammation, immunity and susceptibility to HIV-1

The indigenous microbiota lining mucosal tissues in the human body modulate physiology and immunity at these sites. Although the majority of research demonstrating microbial manipulation of host immune responses has been conducted in the intestinal tract and is reviewed elsewhere ([13]; [83]; [144]), increasing evidence suggests that the VMB plays similar immunomodulatory roles. Unlike the gut microbiome, in which bacterial diversity is associated with health ([89]), the VMB tends to have low diversity and be predominantly composed of Lactobacillus species ([138]). Lactobacilluscrispatus in particular appears to correlate with protection against STIs and adverse reproductive outcomes via a variety of mechanisms reviewed elsewhere ([9]; [108]; [129]). However, the composition of the VMB varies by ethnicity ([189]); 80-90% of Caucasian and Asian women and 60% of black and Hispanic women typically have Lactobacillus-dominant VMBs ([138]). This suggests that host genetics might be capable, at least in part, of affecting the bacterial species that colonize the FGT, perhaps via subtle differences in vaginal immunity. It is however important to note that the relationship between the VMB and ethnicity is complex and might rather reflect differences in vaginal hygiene practices, a differential risk of other STIs and/or sexual networks, amongst other factors ([18]; [21]; [23]; [28]; [41]; [53]; [57]; [100]; [121]; [151]; [174]; [178]). Taken together, ethnicity alone is not likely to explain the composition of the VMB in individual women, and a comprehensive review of the factors affecting VMB composition is warranted.

As mentioned previously, certain species of lactobacilli appear to be protective against HIV-1, and prospective studies have shown that women with Lactobacillus-dominant VMB are not as likely to acquire HIV-1 as those with more diverse VMB ([67]; [98]; [126]). However, the species of Lactobacillus seems important, as Lactobacillusiners did not have as strong of a protective effect against HIV-1 as other species of lactobacilli ([67]). The main mechanism by which vaginal bacteria are believed to modify HIV-1 risk is by altering local inflammation and HIV-1 target cell populations (CD4+HLA-DR+CD38+CCR5+ cells) ([67]; [96]). At present, it is difficult to discern the precise mechanism by which vaginal bacteria manipulate HIV-1 target cells within the vaginal mucosa. However, in vitro bacterial co-culture with VK2/E6E7 vaginal epithelial cells has shown that certain bacterial genera (Fusobacterium, Aerococcus, Sneathia, Gemella, Mobiluncus and Prevotella) induce secretion of pro-inflammatory cytokines, including IL-1α, IL-1β, TNF-α, IL-8 and RANTES, by activating cellular TLRs ([8]; [51]). Conversely, pro-inflammatory cytokines are not induced when vaginal epithelial cells are co-cultured with L. crispatus (considered to be protective against HIV-1) or other vaginal commensals (Box 1) ([37]; [142]), suggesting that epithelial cells sense bacteria via TLRs in a species-specific manner. Clinical studies have demonstrated direct correlations between non-Lactobacillus-dominant VMBs and increased levels of inflammatory cyto- and chemokines in the vagina, including TNF-α, IFN-γ, IL-1α, IL-1β, IL-8, IL-10, IL-17, IL-23, MIP-1α and MIP-1β ([8]; [67]), supporting the in vitro results. Genital APCs also sense vaginal microbes. Phenotypic and transcriptional profiling of genital APCs collected from women with highly diverse VMBs demonstrated that APCs likely contribute to genital inflammation by responding via TLR-4, activating NF-κB, inducing chemokine secretion and recruiting HIV-1 target cells ([8]). Thus, vaginal bacteria sensed by genital epithelial cells and APCs likely manipulate vaginal inflammation, and can thereby influence susceptibility to HIV-1.

In addition to enhancing HIV-1 target cell recruitment, another mechanism by which vaginal bacteria might enhance susceptibility to HIV-1 is via the breakdown of the vaginal epithelial barrier. As previously mentioned, vaginal bacteria can induce pro-inflammatory cytokines. When primary genital epithelial cells respond to in vitro HIV-1 infection, they secrete pro-inflammatory cytokines (TNF-α, IL-6, IL-8, IP-10, RANTES), which results in decreased trans-epithelial resistance (which is a measure of epithelial barrier integrity), disruption of ZO-1 and occludin, and increased leakage of blue dextran dye across the cellular monolayer. This suggests that vaginal bacteria may also impair mucosal barrier function via their induction of pro-inflammatory cytokines ([49]; [118]). Additional evidence supporting the involvement of the VMB in vaginal epithelial barrier impairment can be gleaned from in vivo studies linking dysbiosis (Box 1) and increased inflammatory cytokines with altered vaginal proteases and mucosal proteins ([12]; [20]). This link was stronger during the luteal phase of the menstrual cycle, when progesterone is high ([16]). Furthermore, impairing the integrity of the vaginal epithelial barrier allows for microbial translocation ([118]), and this might further perpetuate the recruitment and activation of immune cells, including HIV-1 target cells, above the level that would otherwise occur as a result of bacterial sensing by epithelial and APC TLRs alone. Taken together, the VMB can manipulate susceptibility to HIV-1 by modifying both inflammation and integrity of the FGT barrier.

Effect of hormones on the vaginal microbiota

Researchers can glean undeniable evidence for the role of sex hormones in shaping the composition of the VMB from studying pubertal girls, women at menopause, animal models and in vitro bacterial co-culture. Although the VMB is relatively stable, the major hormonal shifts that occur around puberty ([60]; [76]; [77]) significantly change its composition from mainly anaerobic bacteria ([6]) to one dominated by lactobacilli. At menopause, when estrogen levels decrease significantly, the VMB is less likely to be dominated by lactobacilli than in pre- and peri-menopausal women. Post-menopausal women were at 7.8-times greater odds of being colonized by a diverse array of bacteria than pre-menopausal women ([25]; [154]). Estradiol is thought to be a main driver in shifting the VMB towards Lactobacillus dominance, although the mechanisms by which this occurs remain incompletely understood. Estradiol-based hormone replacement therapy (HRT; Box 1) maintains Lactobacillus dominance in post-menopausal women ([25]; [64]; [154]), supporting a link between estradiol and lactobacilli. Additionally, estradiol can increase adhesion of lactobacilli to epithelial cells ([158]), and was proposed to enhance glycogen deposition in the human vaginal epithelium ([35]; [45]), via an unknown mechanism. Glycogen, a glucose polysaccharide and an important nutrient for lactobacilli ([35]; [109]; [127]), can be synthesized by vaginal epithelial cells and released into the vaginal mucus (Fig. 1). Experimental administration of estradiol can induce glycogen deposition in vaginal tissues in hamsters and non-human primates ([68]; [69]) via an unknown mechanism. The availability of glycogen in the epithelial cells is thought to select for vaginal colonization by microbes capable of metabolizing it. However, the relationship between estradiol, free glycogen released into the vaginal lumen by the epithelial cells and lactobacilli may not be as simple, as recent studies did not find a direct correlation between circulating peripheral estradiol and free glycogen ([110]; [108]), and few, if any, species of vaginal lactobacilli directly metabolize glycogen ([101]; [125]; [159]; [160]). The lack of correlation between estradiol and free glycogen could be due to the fact that estradiol concentrations fluctuate rapidly over the menstrual cycle, peripheral estradiol concentrations are generally lower than those in the FGT, and free glycogen might be differentially utilized or degraded depending on the composition of the VMB ([110]). Furthermore, α-amylase, an enzyme that cleaves glycogen into simple sugars, has been isolated in fluid from the lower FGT ([159]). This suggests that, rather than metabolizing glycogen, certain bacterial species in the VMB might directly use the simple sugars as substrates. Nevertheless, high free glycogen is associated with a Lactobacillus-dominant VMB ([109]), and a clear relationship exists between estradiol and vaginal lactobacilli in post-menopausal women on HRT ([25]; [154]), albeit via incompletely understood mechanisms.

Although endogenous hormones can shape the VMB, we are only beginning to explore the modulation of the vaginal bacteria by hormonal contraceptives ([3]; [24]). This is a timely and controversial topic, due to the potential for hormone-VMB interactions to manipulate HIV-1 target cells in the reproductive tract mucosa. Meta-analyses show that women on DMPA are 40% more likely to acquire HIV-1 than women that do not use hormonal contraceptives ([115]; [132]). In 2015, 56 million women worldwide used injectable hormonal contraceptives ([168]). Therefore, understanding their impact on vaginal microbes is of great importance. Indeed, a recent study found that the strongest independent predictors of genital inflammation were use of hormonal contraceptives (all methods grouped) and a VMB subtype that predominantly included women with high Nugent scores (indicating high microbial diversity) ([96]). These findings suggest that both hormonal contraceptives and the vaginal microbes are able to modify HIV-1 target cells in the vaginal mucosa. Previous studies that only examined a targeted subset of the VMB and did not employ 16S rRNA gene sequencing (Box 1) did not find use of hormonal contraceptives to be a confounder of VMB composition ([19]), and showed that women on hormonal contraceptives were more likely to have Lactobacillusfermentum in their VMB than those who were not ([88]). Moreover, the initiation of DMPA injections decreased G. vaginalis and total bacterial load ([145]), and it also reduced the proportion of women harboring H2O2-producing Lactobacillus ([111]). Additionally, a quantitative-PCR-based study quantified five Lactobacillus and four BV-associated species to demonstrate that DMPA was associated with lower quantities of lactobacilli compared to women not using hormonal contraceptives, even excluding BV as a potential confounder ([84]). Although the aforementioned studies included women on a variety of systemically administered hormonal contraceptives such as injectables, oral pills, patches, etc., emerging data suggests that estrogen-containing vaginal rings, which are topically administered, may have a more profound effect on vaginal lactobacilli due to their proximity in the vaginal tract ([36]; [71]; [81]; [170]). Thus, the route of administration of hormonal contraceptives is likely to differentially impact the VMB, and this should be kept in mind for multi-purpose HIV-1 prevention strategies aimed at combining antiretroviral therapy and hormonal contraceptives.

Next-generation 16S rRNA gene sequencing of the VMB demonstrated that VMBs from individual women do not cluster together by method of contraception ([18]; [26]), suggesting that, although hormonal contraceptives did not cause major changes in the VMB, subtle changes may be biologically relevant. Indeed, a recent 16S rRNA sequencing study found that women on oral contraceptives had enhanced L. crispatus and decreased BV-associated bacteria loads ([22]), supporting the findings of meta-analyses showing that hormonal contraceptives can reduce the risk of BV by up to 30% ([169]; [173]). As many of the prior studies did not consider the specific method of (hormonal) contraception (i.e. grouping all contraception or all progestins) or the duration of hormonal contraceptive treatment as independent variables, and did not account for the potential confounding effect of including women with BV, the true effect of hormonal contraceptives on the VMB has been difficult to discern. To address this, our group is conducting 16S rRNA gene sequencing in a comprehensive cross-sectional clinical study where we control for many potential confounders. We aimed to examine the effect of hormonal contraceptives on VMB alpha-diversity (Box 1) and the vaginal microenvironment. We thought that this was particularly warranted given recent publications, which demonstrated that women with non-Lactobacillus-dominant VMB were at greater risk of HIV-1 infection ([67]), and which identified hormonal contraceptives and a diverse VMB as the strongest predictors of genital inflammation ([96]). Taken together, we propose that one of the mechanisms by which DMPA enhances susceptibility to HIV-1 may result from its hypo-estrogenic effect. In the absence of estradiol, the vaginal epithelium and/or mucus may become depleted of Lactobacillus-promoting glycogen, which subsequently allows a diverse array of bacteria to colonize. Consequently, this diverse microbiota might enhance mucosal inflammation and/or HIV-1 target cell activation, and thus enhance susceptibility to HIV-1 infection. A summary of how DMPA might modulate the VMB and susceptibility to HIV-1 in women is presented in Fig. 4. Fig. 4.

The sex-hormone–microbiome–immunity axis and HIV-1 susceptibility in women. An illustration depicting how the hormonal milieu of the lower female genital tract (FGT) might impact susceptibility to HIV-1. (A) Anatomy of the FGT. (B,C) Immunity and the microbiota in the lower FGT. (B) When estradiol is dominant, glycogen, a glucose polysaccharide that is correlated with enhanced vaginal lactobacilli, is abundant and adequately sustains the colonization of the vaginal mucosa by Lactobacillus species, via unknown mechanisms. Several studies have reported that a vaginal microbiota (VMB) dominated by species of lactobacilli is protective against HIV-1, perhaps a result of dampened innate inflammation and a reduction in activated T cells. In a microenvironment influenced by estradiol, epidemiological and experimental studies collectively suggest that susceptibility to HIV-1 appears to be hampered ([70]). (C) Conversely, when DMPA (MPA is the active ingredient in DMPA) is dominant, endogenous estradiol is suppressed due to the hypo-estrogenic effect of DMPA. As a result, glycogen deposition in the vaginal epithelium may be minimized, depleting one of the important nutrients that may sustain the protective vaginal lactobacilli. Given the depletion in nutrients, lactobacilli are not as numerous as when they are under the influence of estradiol, and a more diverse array of bacteria is subsequently supported in the VMB. In turn, the diverse bacteria might induce innate immunity in the FGT, upregulating cytokines, inflammation and activated T cells. Given that activated T cells are a major target of HIV-1, this type of environment would ultimately enhance susceptibility to HIV-1 in women. At present, it is unclear whether this proposed mechanism is a direct result of exposure to DMPA or an indirect result of hypo-estrogenism. AMPs, antimicrobial peptides; DMPA, depot-medroxyprogesterone acetate; HIV-1, human immunodeficiency virus type 1; MPA, medroxyprogesterone acetate.

Conclusions

Herein, we have summarized the current literature and our view of how the sex-hormone–microbiome–immunity axis has the potential to affect HIV-1 susceptibility in women. Factors that enhance inflammation/inflammatory cytokines, and thus HIV-1 target cells, in the FGT can modify the risk of infection. Factors that affect the integrity of the protective epithelial barrier in the FGT can also modify the risk of HIV-1 infection by allowing viral particles to access target cells more readily. Although a relatively recent finding, factors that modify the vaginal microbiota are also believed to be able to modify HIV-1 risk via their impact on both inflammation and barrier integrity. Moving forward, rigorous clinical and preclinical studies aimed at examining how hormonal contraceptives affect the vaginal microbiota are critically needed. Understanding the factors that influence VMB composition, and the mechanisms by which these bacteria modify host factors, including the population of HIV-1 target cells, may help in understanding why women using DMPA as a contraceptive are up to 40% more likely to acquire HIV-1 than women not using hormonal contraceptives ([67]).

Acknowledgements

Acknowledgements

The authors thank and acknowledge the contributions of members of the Kaushic lab over the years who have contributed to the papers cited in this Review. The authors also acknowledge the artwork of Medical Illustrator Nancy Chu Ji in Fig. 4 and for elements of Fig. 1. The authors acknowledge Philip Nguyen for the original design of Fig.1.

References

  1. N. S. Abbai, H. Wand and G. Ramjee (2016). Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban. BMC Womens Health16, 19-1910.1186/s12905-016-0295-5
  2. L. Aboud, T. B. Ball, A. Tjernlund and A. Burgener (2014). The role of serpin and cystatin antiproteases in mucosal innate immunity and their defense against HIV. Am. J. Reprod. Immunol.71, 12-23. 10.1111/aji.1216624325760
  3. S. L. Achilles and S. L. Hillier (2013). The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. AIDS27Suppl. 1, S5-S15. 10.1097/QAD.000000000000005824088684
  4. S. L. Achilles, M. D. Creinin, K. A. Stoner, B. A. Chen, L. Meyn and S. L. Hillier (2014). Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am. J. Obstet. Gynecol.211, 489.e1-910.1016/j.ajog.2014.05.01624834865
  5. S. L. Achilles, M. N. Austin, L. A. Meyn, F. Mhlanga, Z. M. Chirenje and S. L. Hillier (2018). Impact of contraceptive initiation on vaginal microbiota. Am. J. Obstet. Gynecol.218, 622.e1-622.e10. 10.1016/j.ajog.2018.02.01729505773
  6. M. I. Alvarez-Olmos, M. M. Barousse, L. Rajan, B. J. Van Der Pol, D. Fortenberry, D. Orr and P. L. Fidel (2004). Vaginal lactobacilli in adolescents: presence and relationship to local and systemic immunity, and to bacterial vaginosis. Sex. Transm. Dis.31, 393-400. 10.1097/01.OLQ.0000130454.83883.E915215693
  7. R. Amsel, P. A. Totten, C. A. Spiegel, K. C. Chen, D. Eschenbach and K. K. Holmes (1983). Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med.74, 14-22. 10.1016/0002-9343(83)91112-96600371
  8. M. N. Anahtar, E. H. Byrne, K. E. Doherty, B. A. Bowman, H. S. Yamamoto, M. Soumillon, N. Padavattan, N. Ismail, A. Moodley, M. E. Sabatiniet al. (2015). Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity42, 965-976. 10.1016/j.immuni.2015.04.01925992865
  9. M. N. Anahtar, D. B. Gootenberg, C. M. Mitchell and D. S. Kwon (2018). Cervicovaginal microbiota and reproductive health: the virtue of simplicity. Cell Host Microbe23, 159-168. 10.1016/j.chom.2018.01.01329447695
  10. D. J. Anderson, J. Marathe and J. Pudney (2014). The structure of the human vaginal stratum corneum and its role in immune defense. Am. J. Reprod. Immunol.71, 618-623. 10.1111/aji.1223024661416
  11. V. C. Anipindi, P. Bagri, K. Roth, S. E. Dizzell, P. V. Nguyen, C. R. Shaler, D. K. Chu, R. Jiménez-Saiz, H. Liang, S. Swiftet al. (2016). Estradiol enhances CD4+ T-cell anti-viral immunity by priming vaginal DCs to Induce Th17 responses via an IL-1-dependent pathway. PLoS Pathog.12, e100558910.1371/journal.ppat.100558927148737
  12. K. B. Arnold, A. Burgener, K. Birse, L. Romas, L. J. Dunphy, K. Shahabi, M. Abou, G. R. Westmacott, S. McCorrister, J. Kwatamporaet al. (2016). Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins and an influx of HIV-susceptible target cells. Mucosal Immunol.9, 194-205. 10.1038/mi.2015.5126104913
  13. E. Arranz, A. S. Peña and D. Bernardo (2013). Mediators of inflammation and immune responses in the human gastrointestinal tract. Mediat. Inflamm.2013, 86563810.1155/2013/865638
  14. J. Atashili, C. Poole, P. M. Ndumbe, A. A. Adimora and J. S. Smith (2008). Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS22, 1493-1501. 10.1097/QAD.0b013e3283021a3718614873
  15. L. Ballweber, B. Robinson, A. Kreger, M. Fialkow, G. Lentz, M. J. McElrath and F. Hladik (2011). Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. J. Virol.85, 13443-13447. 10.1128/JVI.05615-1121976645
  16. K. Birse, K. B. Arnold, R. M. Novak, S. McCorrister, S. Shaw, G. R. Westmacott, T. B. Ball, D. A. Lauffenburger and A. Burgener (2015a). Molecular signatures of immune activation and epithelial barrier remodeling are enhanced during the luteal phase of the menstrual cycle: implications for HIV susceptibility. J. Virol.89, 8793-8805. 10.1128/JVI.00756-1526085144
  17. K. D. M. Birse, A. L. Cole, T. Hirbod, L. McKinnon, T. B. Ball, G. R. Westmacott, J. Kimani, F. Plummer, A. M. Cole, A. Burgeneret al. (2015b). Non-cationic proteins are associated with HIV neutralizing activity in genital secretions of female sex workers. PLoS ONE10, e013040410.1371/journal.pone.013040426090884
  18. K. D. Birse, L. M. Romas, B. L. Guthrie, P. Nilsson, R. Bosire, J. Kiarie, C. Farquhar, K. Broliden and A. D. Burgener (2017). Genital injury signatures and microbiome alterations associated with depot medroxyprogesterone acetate usage and intravaginal drying practices. J. Infect. Dis.215, 590-598.28011908
  19. H. Borgdorff, M. C. Verwijs, F. W. N. M. Wit, E. Tsivtsivadze, G. F. Ndayisaba, R. Verhelst, F. H. Schuren and J. H. H. M. van de Wijgert (2015). The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in african sex workers. Sex. Transm. Dis.42, 143-152. 10.1097/OLQ.000000000000024525668647
  20. H. Borgdorff, R. Gautam, S. D. Armstrong, D. Xia, G. F. Ndayisaba, N. H. van Teijlingen, T. B. H. Geijtenbeek, J. M. Wastling and J. H. H. M. van de Wijgert (2016). Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier. Mucosal Immunol.9, 621-633. 10.1038/mi.2015.8626349657
  21. C. S. Bradshaw, S. M. Walker, L. A. Vodstrcil, J. E. Bilardi, M. Law, J. S. Hocking, K. A. Fethers, G. Fehler, S. Petersen, S. N. Tabriziet al. (2014). The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW health study. J. Infect. Dis.209, 1562-1572. 10.1093/infdis/jit66424285846
  22. J. P. Brooks, D. J. Edwards, D. L. Blithe, J. M. Fettweis, M. G. Serrano, N. U. Sheth, J. F. Strauss, G. A. Buck and K. K. Jefferson (2017). Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. Contraception95, 405-413. 10.1016/j.contraception.2016.11.00627913230
  23. R. M. Brotman, K. G. Ghanem, M. A. Klebanoff, T. E. Taha, D. O. Scharfstein and J. M. Zenilman (2008). The effect of vaginal douching cessation on bacterial vaginosis: a pilot study. Am. J. Obstet. Gynecol.198, 628.e1-710.1016/j.ajog.2007.11.04318295180
  24. R. M. Brotman, J. Ravel, P. M. Bavoil, P. E. Gravitt and K. G. Ghanem (2014a). Microbiome, sex hormones, and immune responses in the reproductive tract: Challenges for vaccine development against sexually transmitted infections. Vaccine32, 1543-1552. 10.1016/j.vaccine.2013.10.01024135572
  25. R. M. Brotman, M. D. Shardell, P. Gajer, D. Fadrosh, K. Chang, M. I. Silver, R. P. Viscidi, A. E. Burke, J. Ravel and P. E. Gravitt (2014b). Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause21, 450-458. 10.1097/GME.0b013e3182a4690b24080849
  26. E. H. Byrne, M. N. Anahtar, K. E. Cohen, A. Moodley, N. Padavattan, N. Ismail, B. A. Bowman, G. S. Olson, A. Mabhula, A. Leslieet al. (2016). Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet. Infect. Dis.16, 441-448. 10.1016/S1473-3099(15)00429-626723758
  27. A. M. Carias, S. McCoombe, M. McRaven, M. Anderson, N. Galloway, N. Vandergrift, A. J. Fought, J. Lurain, M. Duplantis, R. S. Veazeyet al. (2013). Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J. Virol.87, 11388-11400. 10.1128/JVI.01377-1323966398
  28. B. Chaban, M. G. Links, T. Jayaprakash, E. C. Wagner, D. K. Bourque, Z. Lohn, A. Y. K. Albert, J. van Schalkwyk, G. Reid, S. M. Hemmingsenet al. (2014). Characterization of the vaginal microbiota of healthy Canadian women through the menstrual cycle. Microbiome2, 23-2310.1186/2049-2618-2-23
  29. N. Chandra, A. R. Thurman, S. Anderson, T. D. Cunningham, N. Yousefieh, C. Mauck and G. F. Doncel (2013). Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res. Hum. Retrovir.29, 592-601. 10.1089/aid.2012.027123189932
  30. C. A. Chappell, C. E. Isaacs, W. Xu, L. A. Meyn, K. Uranker, C. S. Dezzutti, B. J. Moncla and S. L. Hillier (2015). The effect of menopause on the innate antiviral activity of cervicovaginal lavage. Am. J. Obstet. Gynecol.213, 204.e1-610.1016/j.ajog.2015.03.04525818668
  31. R.-Y. Chen, Y.-M. Fan, Q. Zhang, S. Liu, Q. Li, G.-L. Ke, C. Li and Z. You (2015). Estradiol inhibits Th17 cell differentiation through inhibition of RORγT transcription by recruiting the ERα/REA complex to estrogen response elements of the RORγT promoter. J. Immunol.194, 4019-4028. 10.4049/jimmunol.140080625769926
  32. C. Chen, X. Song, W. Wei, H. Zhong, J. Dai, Z. Lan, F. Li, X. Yu, Q. Feng, Z. Wanget al. (2017). The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat. Commun.8, 87510.1038/s41467-017-00901-029042534
  33. M. Christodoulides, J. S. Everson, B. L. Liu, P. R. Lambden, P. J. Watt, E. J. Thomas and J. E. Heckels (2000). Interaction of primary human endometrial cells with Neisseria gonorrhoeae expressing green fluorescent protein. Mol. Microbiol.35, 32-43. 10.1046/j.1365-2958.2000.01694.x10632875
  34. C. Cicala, E. Martinelli, J. P. McNally, D. J. Goode, R. Gopaul, J. Hiatt, K. Jelicic, S. Kottilil, K. Macleod, A. O'Sheaet al. (2009). The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc. Natl. Acad. Sci. USA106, 20877-20882. 10.1073/pnas.091179610619933330
  35. R. Cruickshank and A. Sharman (1934). The biology of the vagina in the human subject. BJOG41, 208-226. 10.1111/j.1471-0528.1934.tb08759.x
  36. F. De Seta, S. Restaino, D. De Santo, G. Stabile, R. Banco, M. Busetti, G. Barbati and S. Guaschino (2012). Effects of hormonal contraception on vaginal flora. Contraception86, 526-529. 10.1016/j.contraception.2012.02.01222520642
  37. S. Y. Doerflinger, A. L. Throop and M. M. Herbst-Kralovetz (2014). Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. J. Infect. Dis.209, 1989-1999. 10.1093/infdis/jiu00424403560
  38. B. Dunbar, M. Patel, J. Fahey and C. Wira (2012). Endocrine control of mucosal immunity in the female reproductive tract: impact of environmental disruptors. Mol. Cell. Endocrinol.354, 85-93. 10.1016/j.mce.2012.01.00222289638
  39. L. M. Enomoto, K. J. Kloberdanz, D. G. Mack, D. Elizabeth and A. Weinberg (2007). Ex vivo effect of estrogen and progesterone compared with dexamethasone on cell-mediated immunity of HIV-infected and uninfected subjects. J. Acquired Immune Deficiency Syndromes45, 137-143. 10.1097/QAI.0b013e3180471bae
  40. D. A. Eschenbach, K. Rosene, L. S. Tompkins, H. Watkins and M. G. Gravett (1986). Endometrial cultures obtained by a triple-lumen method from afebrile and febrile postpartum women. J. Infect. Dis.153, 1038-1045. 10.1093/infdis/153.6.10383701115
  41. D. A. Eschenbach, S. S. Thwin, D. L. Patton, T. M. Hooton, A. E. Stapleton, K. Agnew, C. Winter, A. Meier and W. E. Stamm (2000). Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clin. Infect. Dis.30, 901-907. 10.1086/31381810852812
  42. J. Eslahpazir, M.-A. Jenabian, H. Bouhlal, H. Hocini, C. Carbonneil, G. Grésenguet, F.-X. M. Kéou, J. LeGoff, H. Saïdi, M. Requenaet al. (2008). Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clin. Vaccine Immunol.15, 872-884. 10.1128/CVI.00463-0718353923
  43. J. V. Fahey, T. M. Schaefer, J. Y. Channon and C. R. Wira (2005). Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. Hum. Reprod.20, 1439-1446. 10.1093/humrep/deh80615734755
  44. J. V. Fahey, J. A. Wright, L. Shen, J. M. Smith, M. Ghosh, R. M. Rossoll and C. R. Wira (2008). Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture. Mucosal Immunol.1, 317-325. 10.1038/mi.2008.2019079193
  45. M. Farage and H. Maibach (2006). Lifetime changes in the vulva and vagina. Arch. Gynecol. Obstet.273, 195-202. 10.1007/s00404-005-0079-x16208476
  46. V. H. Ferreira, A. Nazli, G. Khan, M. F. Mian, A. A. Ashkar, S. Gray-Owen, R. Kaul and C. Kaushic (2011). Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J. Infect. Dis.204, 299-308. 10.1093/infdis/jir26021673042
  47. V. H. Ferreira, A. Nazli, K. L. Mossman and C. Kaushic (2013). Proinflammatory cytokines and chemokines - but not interferon-β - produced in response to HSV-2 in primary human genital epithelial cells are associated with viral replication and the presence of the Virion host shutoff protein. Am. J. Reprod. Immunol.70, 199-212. 10.1111/aji.1213323621693
  48. V. H. Ferreira, J. K. Kafka and C. Kaushic (2014). Influence of common mucosal co-factors on HIV infection in the female genital tract. Am. J. Reprod. Immunol.71, 543-554. 10.1111/aji.1222124617528
  49. V. H. Ferreira, A. Nazli, S. E. Dizzell, K. Mueller and C. Kaushic (2015). The anti-inflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2. PLoS ONE10, e012490310.1371/journal.pone.012490325856395
  50. R. N. Fichorova, A. O. Cronin, E. Lien, D. J. Anderson and R. R. Ingalls (2002). Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signaling. J. Immunol.168, 2424-2432. 10.4049/jimmunol.168.5.242411859134
  51. R. N. Fichorova, H. S. Yamamoto, M. L. Delaney, A. B. Onderdonk and G. F. Doncel (2011). Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. mBio2, e0016810.1128/mBio.00168-1122027006
  52. R. N. Fichorova, P.-L. Chen, C. S. Morrison, G. F. Doncel, K. Mendonca, C. Kwok, T. Chipato, R. Salata and C. Mauck (2015). The contribution of cervicovaginal infections to the immunomodulatory effects of hormonal contraception. mBio6, e00221-1510.1128/mBio.00221-1526330510
  53. D. S. Forcey, L. A. Vodstrcil, J. S. Hocking, C. K. Fairley, M. Law, R. P. McNair and C. S. Bradshaw (2015). Factors associated with bacterial vaginosis among women who have sex with women: a systematic review. PLoS ONE10, e014190510.1371/journal.pone.014190526675816
  54. J. M. Franasiak, M. D. Werner, C. R. Juneau, X. Tao, J. Landis, Y. Zhan, N. R. Treff and R. T. Scott (2016). Endometrial microbiome at the time of embryo transfer: next-generation sequencing of the 16S ribosomal subunit. J. Assist. Reprod. Genet.33, 129-136. 10.1007/s10815-015-0614-z26547201
  55. R. D. Franklin and W. H. Kutteh (1999). Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J. Reprod. Immunol.42, 93-106. 10.1016/S0165-0378(98)00086-210221733
  56. E. E. Freeman, H. A. Weiss, J. R. Glynn, P. L. Cross, J. A. Whitworth and R. J. Hayes (2006). Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS20, 73-83. 10.1097/01.aids.0000198081.09337.a716327322
  57. P. Gajer, R. M. Brotman, G. Bai, J. Sakamoto, U. M. E. Schutte, X. Zhong, S. S. K. Koenig, L. Fu, Z. Ma, X. Zhouet al. (2012). Temporal dynamics of the human vaginal microbiota. Sci. Transl. Med.4, 132ra5210.1126/scitranslmed.3003605
  58. T. B. H. Geijtenbeek and Y. van Kooyk (2003). DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top. Microbiol. Immunol.276, 31-54. 10.1007/978-3-662-06508-2_212797442
  59. T. B. H. Geijtenbeek, D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. F. van Duijnhoven, J. Middel, I. L. M. H. A. Cornelissen, H. S. L. M. Nottet, V. N. KewalRamani, D. R. Littmanet al. (2000). DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell100, 587-597. 10.1016/S0092-8674(00)80694-710721995
  60. G. J. Gerstner, W. Grünberger, E. Boschitsch and M. Rotter (1982). Vaginal organisms in prepubertal children with and without vulvovaginitis. A Vaginoscopic study. Arch. Gynecol.231, 247-252. 10.1007/BF021101256751240
  61. S. Ghisletti, C. Meda, A. Maggi and E. Vegeto (2005). 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol. Cell. Biol.25, 2957-2968. 10.1128/MCB.25.8.2957-2968.200515798185
  62. M. Ghosh, Z. Shen, J. V. Fahey, S. Cu-Uvin, K. Mayer and C. R. Wira (2010). Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology129, 207-219. 10.1111/j.1365-2567.2009.03165.x19824918
  63. M. Ghosh, Z. Shen, J. V. Fahey, S. G. Crist, M. Patel, J. M. Smith and C. R. Wira (2013). Pathogen recognition in the human female reproductive tract: expression of intracellular cytosolic sensors NOD1, NOD2, RIG-1, and MDA5 and response to HIV-1 and Neisseria gonorrhea. Am. J. Reprod. Immunol.69, 41-51. 10.1111/aji.12019
  64. P. D. Ginkel, D. E. Soper, R. C. Bump and H. P. Dalton (1993). Vaginal flora in postmenopausal women: the effect of estrogen replacement. Infect. Dis. Obstet. Gynecol.1, 94-97. 10.1155/S106474499300022518475325
  65. I. K. Gipson, S. B. Ho, S. J. Spurr-Michaud, A. S. Tisdale, Q. Zhan, E. Torlakovic, J. Pudney, D. J. Anderson, N. W. Toribara and J. A. Hill (1997). Mucin genes expressed by human female reproductive tract epithelia. Biol. Reprod.56, 999-1011. 10.1095/biolreprod56.4.9999096884
  66. A. L. Givan, H. D. White, J. E. Stern, E. Colby, E. J. Gosselin, P. M. Guyre and C. R. Wira (1997). Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am. J. Reprod. Immunol.38, 350-359. 10.1111/j.1600-0897.1997.tb00311.x9352027
  67. C. Gosmann, M. N. Anahtar, S. A. Handley, M. Farcasanu, G. Abu-Ali, B. A. Bowman, N. Padavattan, C. Desai, L. Droit, A. Moodleyet al. (2017). Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young south african women. Immunity46, 29-37. 10.1016/j.immuni.2016.12.01328087240
  68. A. T. Gregoire and P. F. Parakkal (1972). Glycogen content in the vaginal tissue of normally cycling and estrogen and progesterone-treated rhesus monkeys. Biol. Reprod.7, 9-14. 10.1093/biolreprod/7.1.94340454
  69. A. T. Gregoire and D. W. Richardson (1970). Glycogen and water responses to estrogen in the hamster reproductive tract. Endocrinology87, 1369-1372. 10.1210/endo-87-6-13695482715
  70. J. P. Hapgood, C. Kaushic and Z. Hel (2018). Hormonal contraception and HIV-1 acquisition: biological mechanisms. Endocr. Rev.39, 36-78.29309550
  71. L. Hardy, V. Jespers, I. De Baetselier, J. Buyze, L. Mwambarangwe, V. Musengamana, J. van de Wijgert and T. Crucitti (2017). Association of vaginal dysbiosis and biofilm with contraceptive vaginal ring biomass in African women. PLoS ONE12, e017832410.1371/journal.pone.017832428594946
  72. K. M. Hart, A. J. Murphy, K. T. Barrett, C. R. Wira, P. M. Guyre and P. A. Pioli (2009). Functional expression of pattern recognition receptors in tissues of the human female reproductive tract. J. Reprod. Immunol.80, 33-40. 10.1016/j.jri.2008.12.00419406482
  73. D. L. Hemsell, V. L. Obregon, M. C. Heard and B. J. Nobles (1989). Endometrial bacteria in asymptomatic, nonpregnant women. J. Reprod. Med.34, 872-874.2585386
  74. M. M. Herbst-Kralovetz, A. J. Quayle, M. Ficarra, S. Greene, W. A. Rose, R. Chesson, R. A. Spagnuolo and R. B. Pyles (2008). Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am. J. Reprod. Immunol.59, 212-224. 10.1111/j.1600-0897.2007.00566.x18201283
  75. D. K. Hickey, M. V. Patel, J. V. Fahey and C. R. Wira (2011). Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J. Reprod. Immunol.88, 185-194. 10.1016/j.jri.2011.01.00521353708
  76. R. J. Hickey, X. Zhou, M. L. Settles, J. Erb, K. Malone, M. A. Hansmann, M. L. Shew, B. Van Der Pol, J. D. Fortenberry and L. J. Forney (2015). Vaginal microbiota of adolescent girls prior to the onset of menarche resemble those of reproductive-age women. mBio6, e00097-1510.1128/mBio.00097-1525805726
  77. G. B. Hill, K. K. St Claire and L. T. Gutman (1995). Anaerobes predominate among the vaginal microflora of prepubertal girls. Clin. Infect. Dis.20Suppl. 2, S269-S270. 10.1093/clinids/20.Supplement_2.S2697548572
  78. F. Hladik and M. J. McElrath (2008). Setting the stage: host invasion by HIV. Nat. Rev. Immunol.8, 447-457. 10.1038/nri230218469831
  79. H. Hocini, P. Becquart, H. Bouhlal, N. Chomont, P. Ancuta, M. D. Kazatchkine and L. Bélec (2001). Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. J. Virol.75, 5370-5374. 10.1128/JVI.75.11.5370-5374.200111333919
  80. C. F. Houlihan, N. L. Larke, D. Watson-Jones, K. K. Smith-McCune, S. Shiboski, P. E. Gravitt, J. S. Smith, L. Kuhn, C. Wang and R. Hayes (2012). Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS26, 2211-2222. 10.1097/QAD.0b013e328358d90822874522
  81. Y. Huang, R. B. Merkatz, S. L. Hillier, K. Roberts, D. L. Blithe, R. Sitruk-Ware and M. D. Creinin (2015). Effects of a one year reusable contraceptive vaginal ring on vaginal microflora and the risk of vaginal infection: an open-label prospective evaluation. PLoS ONE10, e013446010.1371/journal.pone.013446026267119
  82. R. P. H. Huijbregts, K. G. Michel and Z. Hel (2014). Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. Contraception90, 123-129. 10.1016/j.contraception.2014.02.00624674041
  83. J. Jacobs and J. Braun (2014). Host genes and their effect on the intestinal microbiome garden. Genome Med.6, 11910.1186/s13073-014-0119-x25593597
  84. V. Jespers, J. Kyongo, S. Joseph, L. Hardy, P. Cools, T. Crucitti, M. Mwaura, G. Ndayisaba, S. Delany-Moretlwe, J. Buyzeet al. (2017). A longitudinal analysis of the vaginal microbiota and vaginal immune mediators in women from sub-Saharan Africa. Sci. Rep.7, 1197410.1038/s41598-017-12198-628931859
  85. C. Kaushic (2009). The role of the local microenvironment in regulating susceptibility and immune responses to sexually transmitted viruses in the female genital tract. J. Reprod. Immunol.83, 168-172. 10.1016/j.jri.2009.08.01019857903
  86. C. Kaushic (2011). HIV-1 infection in the female reproductive tract: role of interactions between HIV-1 and genital epithelial cells. Am. J. Reprod. Immunol.65, 253-260. 10.1111/j.1600-0897.2010.00965.x21223427
  87. C. Kaushic, K. L. Roth, V. Anipindi and F. Xiu (2011). Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. J. Reprod. Immunol.88, 204-209. 10.1016/j.jri.2010.12.00421296427
  88. Y. F. Kazi, S. Saleem and N. Kazi (2012). Investigation of vaginal microbiota in sexually active women using hormonal contraceptives in Pakistan. BMC Urol.12, 2210.1186/1471-2490-12-2222901000
  89. J. M. Kinross, A. W. Darzi and J. K. Nicholson (2011). Gut microbiome-host interactions in health and disease. Genome Med.3, 14-1410.1186/gm228
  90. Y. Kumamoto and A. Iwasaki (2012). Unique features of antiviral immune system of the vaginal mucosa. Curr. Opin. Immunol.24, 411-416. 10.1016/j.coi.2012.05.00622673876
  91. W. H. Kutteh, Z. Moldoveanu and J. Mestecky (1998). Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res. Hum. Retrovir.14Suppl. 1, S51-S55.9581884
  92. S. K. Lai, K. Hida, S. Shukair, Y.-Y. Wang, A. Figueiredo, R. Cone, T. J. Hope and J. Hanes (2009). Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J. Virol.83, 11196-11200. 10.1128/JVI.01899-0819692470
  93. J. Lajoie, J. Juno, A. Burgener, S. Rahman, K. Mogk, C. Wachihi, J. Mwanjewe, F. A. Plummer, J. Kimani, T. B. Ballet al. (2012). A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers. Mucosal Immunol.5, 277-287. 10.1038/mi.2012.722318497
  94. P. Łaniewski, A. Gomez, G. Hire, M. So and M. M. Herbst-Kralovetz (2017). Human three-dimensional endometrial epithelial cell model to study host interactions with vaginal bacteria and Neisseria gonorrhoeae. Infect. Immun.85, e01049-e0101610.1128/IAI.01049-16
  95. S. K. Lee, C. J. Kim, D.-J. Kim and J.-H. Kang (2015). Immune cells in the female reproductive tract. Immune Network15, 16-26. 10.4110/in.2015.15.1.1625713505
  96. K. Lennard, S. Dabee, S. L. Barnabas, E. Havyarimana, A. Blakney, S. Z. Jaumdally, G. Botha, N. N. Mkhize, L.-G. Bekker, D. A. Lewiset al. (2017). Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in adolescent South African women. Infect. Immun.86, e00410-e00417. 10.1128/IAI.00410-1729038128
  97. Z. Li, S. Palaniyandi, R. Zeng, W. Tuo, D. C. Roopenian and X. Zhu (2011). Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc. Natl. Acad. Sci. USA108, 4388-4393. 10.1073/pnas.101286110821368166
  98. N. Low, M. F. Chersich, K. Schmidlin, M. Egger, S. C. Francis, J. H. H. M. van de Wijgert, R. J. Hayes, J. M. Baeten, J. Brown, S. Delany-Moretlweet al. (2011). Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med.8, e100041610.1371/journal.pmed.100041621358808
  99. B. Ma, L. J. Forney and J. Ravel (2012). Vaginal microbiome: rethinking health and disease. Annu. Rev. Microbiol.66, 371-389. 10.1146/annurev-micro-092611-15015722746335
  100. J. M. Marrazzo, L. A. Koutsky, D. A. Eschenbach, K. Agnew, K. Stine and S. L. Hillier (2002). Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J. Infect. Dis.185, 1307-1313. 10.1086/33988412001048
  101. R. Martín, N. Soberón, M. Vaneechoutte, A. B. Flórez, F. Vázquez and J. E. Suárez (2008). Characterization of indigenous vaginal lactobacilli from healthy women as probiotic candidates. Int. Microbiol.11, 261-266.19204898
  102. L. Masson, J.-A. S. Passmore, L. J. Liebenberg, L. Werner, C. Baxter, K. B. Arnold, C. Williamson, F. Little, L. E. Mansoor, V. Naranbhaiet al. (2015). Genital inflammation and the risk of HIV acquisition in women. Clin. Infect. Dis.61, 260-269. 10.1093/cid/civ29825900168
  103. L. R. McKinnon, B. Nyanga, D. Chege, P. Izulla, M. Kimani, S. Huibner, L. Gelmon, K. E. Block, C. Cicala, A. O. Anzalaet al. (2011). Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J. Immunol.187, 6032-6042. 10.4049/jimmunol.110183622048765
  104. L. R. McKinnon, B. Nyanga, C. J. Kim, P. Izulla, J. Kwatampora, M. Kimani, K. Shahabi, N. Mugo, J. S. Smith, A. O. Anzalaet al. (2015). Early HIV-1 infection is associated with reduced frequencies of cervical Th17 cells. JAIDS J. Acquir. Immune Defic. Syndr.68, 6-12. 10.1097/QAI.000000000000038925296095
  105. T. B. McNeely, M. Dealy, D. J. Dripps, J. M. Orenstein, S. P. Eisenberg and S. M. Wahl (1995). Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Invest.96, 456-464. 10.1172/JCI1180567615818
  106. K. G. Michel, R. P. H. Huijbregts, J. L. Gleason, H. E. Richter and Z. Hel (2015). Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract. JAIDS J. Acquir. Immune Defic. Syndr.68, 511-518. 10.1097/QAI.000000000000053125763784
  107. C. J. Miller and R. J. Shattock (2003). Target cells in vaginal HIV transmission. Microbes Infect.5, 59-67. 10.1016/S1286-4579(02)00056-412593974
  108. P. Mirmonsef and G. T. Spear (2014). The barrier to HIV transmission provided by genital tract lactobacillus colonization. Am. J. Reprod. Immunol.71, 531-536. 10.1111/aji.1223224661438
  109. P. Mirmonsef, A. L. Hotton, D. Gilbert, D. Burgad, A. Landay, K. M. Weber, M. Cohen, J. Ravel and G. T. Spear (2014). Free glycogen in vaginal fluids is associated with lactobacillus colonization and low vaginal pH. PLoS ONE9, e102467-e10246710.1371/journal.pone.0102467
  110. P. Mirmonsef, A. L. Hotton, D. Gilbert, C. J. Gioia, D. Maric, T. J. Hope, A. L. Landay and G. T. Spear (2016). Glycogen levels in undiluted genital fluid and their relationship to vaginal pH, estrogen, and progesterone. PLoS ONE11, e015355310.1371/journal.pone.015355327093050
  111. C. M. Mitchell, L. McLemore, K. Westerberg, R. Astronomo, K. Smythe, C. Gardella, M. Mack, A. Magaret, D. Patton, K. Agnewet al. (2014). Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. J. Infect. Dis.210, 651-655. 10.1093/infdis/jiu17624652495
  112. C. M. Mitchell, A. Haick, E. Nkwopara, R. Garcia, M. Rendi, K. Agnew, D. N. Fredricks and D. Eschenbach (2015). Colonization of the upper genital tract by vaginal bacterial species in nonpregnant women. Am. J. Obstet. Gynecol.212, 611.e1-611.e9. 10.1016/j.ajog.2014.11.04325524398
  113. B. R. Møller, F. V. Kristiansen, P. Thorsen, L. Frost and S. C. Mogensen (1995). Sterility of the uterine cavity. Acta Obstet. Gynecol. Scand.74, 216-219. 10.3109/000163495090089427900526
  114. I. Moreno, F. M. Codoñer, F. Vilella, D. Valbuena, J. F. Martinez-Blanch, J. Jimenez-Almazán, R. Alonso, P. Alamá, J. Remohí, A. Pelliceret al. (2016). Evidence that the endometrial microbiota has an effect on implantation success or failure. Am. J. Obstet. Gynecol.215, 684-703. 10.1016/j.ajog.2016.09.07527717732
  115. C. S. Morrison, P.-L. Chen, C. Kwok, J. M. Baeten, J. Brown, A. M. Crook, L. Van Damme, S. Delany-Moretlwe, S. C. Francis, B. A. Friedlandet al. (2015). Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med.12, e1001778-e100177810.1371/journal.pmed.1001778
  116. C. A. Muzny and J. R. Schwebke (2016). Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses. J. Infect. Dis.214, S1-S5. 10.1093/infdis/jiw12127449868
  117. A. Nazli, X.-D. Yao, M. Smieja, K. L. Rosenthal, A. A. Ashkar and C. Kaushic (2009). Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women. Antivir. Res.81, 103-112. 10.1016/j.antiviral.2008.10.00519013198
  118. A. Nazli, O. Chan, W. N. Dobson-Belaire, M. Ouellet, M. J. Tremblay, S. D. Gray-Owen, A. L. Arsenault and C. Kaushic (2010). Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog.6, e100085210.1371/journal.ppat.100085220386714
  119. A. Nazli, J. K. Kafka, V. H. Ferreira, V. Anipindi, K. Mueller, B. J. Osborne, S. Dizzell, S. Chauvin, M. F. Mian, M. Ouelletet al. (2013). HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium. J. Immunol.191, 4246-4258. 10.4049/jimmunol.130148224043886
  120. A. Nazli, S. Dizzell, M. A. Zahoor, V. H. Ferreira, J. Kafka, M. W. Woods, M. Ouellet, A. A. Ashkar, M. J. Tremblay, D. M. E. Bowdishet al. (2018). Interferon-β induced in female genital epithelium by HIV-1 glycoprotein 120 via Toll-like-receptor 2 pathway acts to protect the mucosal barrier. Cell. Mol. Immunol.10.1038/cmi.2017.168
  121. Y. H. Neggers, T. R. Nansel, W. W. Andrews, J. R. Schwebke, K.-F. Yu, R. L. Goldenberg and M. A. Klebanoff (2007). Dietary intake of selected nutrients affects bacterial vaginosis in women. J. Nutr.137, 2128-2133. 10.1093/jn/137.9.212817709453
  122. P. V. Nguyen, J. K. Kafka, V. H. Ferreira, K. Roth and C. Kaushic (2014). Innate and adaptive immune responses in male and female reproductive tracts in homeostasis and following HIV infection. Cell. Mol. Immunol.11, 410-427. 10.1038/cmi.2014.4124976268
  123. P. V. Nguyen, J. M. Wessels, K. Mueller, F. Vahedi, V. Anipindi, C. P. Verschoor, M. Chew, A. Deshiere, U. Karniychuk, T. Mazzulliet al. (2017). Frequency of human CD45+ target cells is a key determinant of intravaginal HIV-1 infection in humanized mice. Sci. Rep.7, 1526310.1038/s41598-017-15630-z29127409
  124. M. K. Norvell, G. I. Benrubi and R. J. Thompson (1984). Investigation of microtrauma after sexual intercourse. J. Reprod. Med.29, 269-271.6716372
  125. K. L. Nunn and L. J. Forney (2016). Unraveling the dynamics of the human vaginal microbiome. Yale J. Biol. Med.89, 331-337.27698617
  126. K. L. Nunn, Y.-Y. Wang, D. Harit, M. S. Humphrys, B. Ma, R. Cone, J. Ravel and S. K. Lai (2015). Enhanced trapping of HIV-1 by human cervicovaginal mucus is associated with lactobacillus crispatus-dominant microbiota. mBio6, e01084-1510.1128/mBio.01084-1526443453
  127. J. Paavonen (1983). Physiology and ecology of the vagina. Scand. J. Infect. Dis. Suppl.40, 31-35.6582587
  128. M. V. Patel, J. V. Fahey, R. M. Rossoll and C. R. Wira (2013). Innate immunity in the vagina (part I): estradiol inhibits HBD2 and elafin secretion by human vaginal epithelial cells. Am. J. Reprod. Immunol.69, 463-474. 10.1111/aji.1207823398087
  129. M. I. Petrova, E. Lievens, S. Malik, N. Imholz and S. Lebeer (2015). Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front. Physiol.6, 8110.3389/fphys.2015.0008125859220
  130. M. P. Piccinni, M. G. Giudizi, R. Biagiotti, L. Beloni, L. Giannarini, S. Sampognaro, P. Parronchi, R. Manetti, F. Annunziato and C. Livi (1995). Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J. Immunol.155, 128-133.7541410
  131. P. A. Pioli, E. Amiel, T. M. Schaefer, J. E. Connolly, C. R. Wira and P. M. Guyre (2004). Differential expression of toll-like receptors 2 and 4 in tissues of the human female reproductive tract. Infect. Immun.72, 5799-5806. 10.1128/IAI.72.10.5799-5806.200415385480
  132. C. B. Polis, K. M. Curtis, P. C. Hannaford, S. J. Phillips, T. Chipato, J. N. Kiarie, D. J. Westreich and P. S. Steyn (2016). An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS30, 2665-2683. 10.1097/QAD.000000000000122827500670
  133. M. Pope and A. T. Haase (2003). Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat. Med.9, 847-852. 10.1038/nm0703-84712835704
  134. M. Prakash, M. S. Kapembwa, F. Gotch and S. Patterson (2002). Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women. J. Reprod. Immunol.54, 117-131. 10.1016/S0165-0378(01)00125-511839399
  135. J. Pudney, A. J. Quayle and D. J. Anderson (2005). Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod.73, 1253-1263. 10.1095/biolreprod.105.04313316093359
  136. A. J. Quayle (2002). The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. J. Reprod. Immunol.57, 61-79. 10.1016/S0165-0378(02)00019-012385834
  137. N. E. Quispe Calla, M. G. Ghonime, T. L. Cherpes and R. D. Vicetti Miguel (2015). Medroxyprogesterone acetate impairs human dendritic cell activation and function. Hum. Reprod.30, 1169-1177. 10.1093/humrep/dev03525740884
  138. J. Ravel, P. Gajer, Z. Abdo, G. M. Schneider, S. S. K. Koenig, S. L. McCulle, S. Karlebach, R. Gorle, J. Russell, C. O. Tacketet al. (2011). Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. USA108Suppl., 4680-4687. 10.1073/pnas.100261110720534435
  139. B. G. Reed and B. R. Carr (2000). The Normal Menstrual Cycle and the Control of Ovulation: in www.endotext.org (ed. De Groot L. J., Chrousos G., Dungan K. et al.). South Dartmouth: MDText.com, Inc.
  140. G. Reid (2018). Is bacterial vaginosis a disease?Appl. Microbiol. Biotechnol.102, 553-558. 10.1007/s00253-017-8659-929177936
  141. M. Rodriguez-Garcia, N. Biswas, M. V. Patel, F. D. Barr, S. G. Crist, C. Ochsenbauer, J. V. Fahey and C. R. Wira (2013). Estradiol reduces susceptibility of CD4+ T cells and macrophages to HIV-infection. PLoS ONE8, e62069-e6206910.1371/journal.pone.0062069
  142. W. A. Rose, C. L. McGowin, R. A. Spagnuolo, T. D. Eaves-Pyles, V. L. Popov and R. B. Pyles (2012). Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures. PLoS ONE7, e3272810.1371/journal.pone.003272822412914
  143. J. A. Ross and A. T. Agwanda (2012). Increased use of injectable contraception in sub-Saharan Africa. Afr. J. Reprod. Health16, 68-80.
  144. J. L. Round and S. K. Mazmanian (2009). The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol.9, 313-323. 10.1038/nri251519343057
  145. A. C. Roxby, D. N. Fredricks, K. Odem-Davis, K. Ásbjörnsdóttir, L. Masese, T. L. Fiedler, S. De Rosa, W. Jaoko, J. N. Kiarie, J. Overbaughet al. (2016). Changes in vaginal microbiota and immune mediators in HIV-1-seronegative kenyan women initiating depot medroxyprogesterone acetate. JAIDS J. Acquir. Immune Defic. Syndr.71, 359-366. 10.1097/QAI.000000000000086626914908
  146. M. W. Russell and J. Mestecky (2002). Humoral immune responses to microbial infections in the genital tract. Microbes Infect.4, 667-677. 10.1016/S1286-4579(02)01585-X12048036
  147. B. S Lashkari and D. O. C. Anumba (2017). Estradiol alters the immune-responsiveness of cervical epithelial cells stimulated with ligands of Toll-like receptors 2 and 4. PLoS ONE12, e017364610.1371/journal.pone.017364628296959
  148. E. Saba, M. Origoni, G. Taccagni, D. Ferrari, C. Doglioni, A. Nava, A. Lisco, J.-C. Grivel, L. Margolis and G. Poli (2013). Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. Mucosal Immunol.6, 1081-1090. 10.1038/mi.2013.223385427
  149. M. Safaeian, R. T. Falk, A. C. Rodriguez, A. Hildesheim, T. Kemp, M. Williams, L. Morera, M. Barrantes, R. Herrero, C. Porraset al. (2009). Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycle. J. Infect. Dis.199, 455-463. 10.1086/59606019133811
  150. T. M. Schaefer, J. A. Wright, P. A. Pioli and C. R. Wira (2005). IL-1beta-mediated proinflammatory responses are inhibited by estradiol via down-regulation of IL-1 receptor type I in uterine epithelial cells. J. Immunol.175, 6509-6516. 10.4049/jimmunol.175.10.650916272305
  151. J. R. Schwebke, C. M. Richey and H. L. Weiss (1999). Correlation of behaviors with microbiological changes in vaginal flora. J. Infect. Dis.180, 1632-1636. 10.1086/31506510515826
  152. J. R. Schwebke, C. A. Muzny and W. E. Josey (2014). Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model. J. Infect. Dis.210, 338-343. 10.1093/infdis/jiu08924511102
  153. R. Shen, H. E. Richter and P. D. Smith (2011). Early HIV-1 target cells in human vaginal and ectocervical mucosa. Am. J. Reprod. Immunol.65, 261-267. 10.1111/j.1600-0897.2010.00939.x21118402
  154. J. Shen, N. Song, C. J. Williams, C. J. Brown, Z. Yan, C. Xu and L. J. Forney (2016). Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci. Rep.6, 2438010.1038/srep2438027103314
  155. Z. Shen, M. Rodriguez-Garcia, C. Ochsenbauer and C. R. Wira (2017). Characterization of immune cells and infection by HIV in human ovarian tissues. Am. J. Reprod. Immunol.78, e12687-e1268710.1111/aji.12687
  156. S. A. Shukair, S. A. Allen, G. C. Cianci, D. J. Stieh, M. R. Anderson, S. M. Baig, C. J. Gioia, E. J. Spongberg, S. M. Kauffman, M. D. McRavenet al. (2013). Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunol.6, 427-434. 10.1038/mi.2012.8722990624
  157. G. F. Shust, S. Cho, M. Kim, R. P. Madan, E. M. Guzman, M. Pollack, J. Epstein, H. W. Cohen, M. J. Keller and B. C. Herold (2010). Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am. J. Reprod. Immunol.63, 110-119. 10.1111/j.1600-0897.2009.00768.x20015330
  158. C. Silva, R. Rey and M. Elena Nader-Macías (2004). Effects of Estrogen Administration on the Colonization Capability of Lactobacilli and Escherichia coli in the Urinary Tracts of Mice, Vol. 268, pp. 387-400. New Jersey: Humana Press.
  159. G. T. Spear, A. L. French, D. Gilbert, M. R. Zariffard, P. Mirmonsef, T. H. Sullivan, W. W. Spear, A. Landay, S. Micci, B.-H. Leeet al. (2014). Human α-amylase present in lower-genital-tract mucosal fluid processes glycogen to support vaginal colonization by lactobacillus. J. Infect. Dis.210, 1019-1028. 10.1093/infdis/jiu23124737800
  160. D. E. S. Stewart-Tull (1964). Evidence that vaginal lactobacilli do not ferment glycogen. Am. J. Obstet. Gynecol.88, 676-679. 10.1016/0002-9378(64)90898-114128200
  161. D. J. Stieh, D. Maric, Z. L. Kelley, M. R. Anderson, H. Z. Hattaway, B. A. Beilfuss, K. B. Rothwangl, R. S. Veazey and T. J. Hope (2014). Vaginal challenge with an SIV-based dual reporter system reveals that infection can occur throughout the upper and lower female reproductive tract. PLoS Pathog.10, e100444010.1371/journal.ppat.100444025299616
  162. R. H. Straub (2007). The complex role of estrogens in inflammation. Endocr. Rev.28, 521-574. 10.1210/er.2007-000117640948
  163. L. Sun, C. M. Finnegan, T. Kish-Catalone, R. Blumenthal, P. Garzino-Demo, G. M. La Terra Maggiore, S. Berrone, C. Kleinman, Z. Wu, S. Abdelwahabet al. (2005). Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J. Virol.79, 14318-14329. 10.1128/JVI.79.22.14318-14329.200516254366
  164. A. Swidsinski, V. Loening-Baucke, W. Mendling, Y. Dörffel, J. Schilling, Z. Halwani, X.-F. Jiang, H. Verstraelen and S. Swidsinski (2014). Infection through structured polymicrobial Gardnerella biofilms (StPM-GB). Histol. Histopathol.29, 567-587.24327088
  165. I. Tchou, L. Misery, O. Sabido, C. Dezutter-Dambuyant, T. Bourlet, P. Moja, H. Hamzeh, J. Peguet-Navarro, D. Schmitt and C. Genin (2001). Functional HIV CXCR4 coreceptor on human epithelial Langerhans cells and infection by HIV strain X4. J. Leukoc. Biol.70, 313-321.11493625
  166. C. Tevi-Bénissan, L. Bélec, M. Lévy, V. Schneider-Fauveau, A. Si Mohamed, M. C. Hallouin, M. Matta and G. Grésenguet (1997). In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin. Diagn. Lab. Immunol.4, 367-374.9144379
  167. R. T. Trifonova, J. Lieberman and D. van Baarle (2014). Distribution of immune cells in the human cervix and implications for HIV transmission. Am. J. Reprod. Immunol.71, 252-264. 10.1111/aji.1219824410939
  168. United Nations Department of Economic and Social Affairs Population Division. (2015). Trends in contraceptive use worldwide 2015.
  169. J. H. H. M. van de Wijgert, M. C. Verwijs, A. N. Turner and C. S. Morrison (2013). Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis. AIDS27, 2141-2153. 10.1097/QAD.0b013e32836290b623660575
  170. S. Veres, L. Miller and B. Burington (2004). A comparison between the vaginal ring and oral contraceptives. Obstet. Gynecol.104, 555-563. 10.1097/01.AOG.0000136082.59644.1315339769
  171. H. Verstraelen, R. Vilchez-Vargas, F. Desimpel, R. Jauregui, N. Vankeirsbilck, S. Weyers, R. Verhelst, P. De Sutter, D. H. Pieper and T. Van De Wiele (2016). Characterisation of the human uterine microbiome in non-pregnant women through deep sequencing of the V1-2 region of the 16S rRNA gene. PeerJ4, e160210.7717/peerj.160226823997
  172. D. Vitali, J. M. Wessels and C. Kaushic (2017). Role of sex hormones and the vaginal microbiome in susceptibility and mucosal immunity to HIV-1 in the female genital tract. AIDS Res. Ther.14, 39-3910.1186/s12981-017-0169-4
  173. L. A. Vodstrcil, J. S. Hocking, M. Law, S. Walker, S. N. Tabrizi, C. K. Fairley and C. S. Bradshaw (2013). Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS ONE8, e7305510.1371/journal.pone.007305524023807
  174. L. A. Vodstrcil, J. Twin, S. M. Garland, C. K. Fairley, J. S. Hocking, M. G. Law, E. L. Plummer, K. A. Fethers, E. P. F. Chow, S. N. Tabriziet al. (2017). The influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade diversity in young women. PLoS ONE12, e017185610.1371/journal.pone.017185628234976
  175. R. D. Wagner and S. J. Johnson (2012). Probiotic lactobacillus and estrogen effects on vaginal epithelial gene expression responses to Candida albicans. J. Biomed. Sci.19, 58-5810.1186/1423-0127-19-58
  176. M. R. S. Walther-António, J. Chen, F. Multinu, A. Hokenstad, T. J. Distad, E. H. Cheek, G. L. Keeney, D. J. Creedon, H. Nelson, A. Marianiet al. (2016). Potential contribution of the uterine microbiome in the development of endometrial cancer. Genome Med.8, 12210.1186/s13073-016-0368-y27884207
  177. B. A. Wee, M. Thomas, E. L. Sweeney, F. D. Frentiu, M. Samios, J. Ravel, P. Gajer, G. Myers, P. Timms, J. A. Allanet al. (2018). A retrospective pilot study to determine whether the reproductive tract microbiota differs between women with a history of infertility and fertile women. Aust. New Zealand J. Obstetrics Gynaecol.58, 341-348. 10.1111/ajo.12754
  178. J. M. Wessels, J. Lajoie, D. Vitali, K. Omollo, J. Kimani, J. Oyugi, J. Cheruiyot, M. Kimani, J. N. Mungai, M. Akoloet al. (2017). Association of high-risk sexual behaviour with diversity of the vaginal microbiota and abundance of Lactobacillus. PLoS ONE12, e018761210.1371/journal.pone.018761229095928
  179. H. D. White, K. M. Crassi, A. L. Givan, J. E. Stern, J. L. Gonzalez, V. A. Memoli, W. R. Green and C. R. Wira (1997a). CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J. Immunol.158, 3017-3027.9058841
  180. H. D. White, G. R. Yeaman, A. L. Givan and C. R. Wira (1997b). Mucosal immunity in the human female reproductive tract: cytotoxic T lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women. Am. J. Reprod. Immunol.37, 30-38. 10.1111/j.1600-0897.1997.tb00190.x9138451
  181. F. Wieser, J. Hosmann, W. Tschugguel, K. Czerwenka, R. Sedivy and J. C. Huber (2001). Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertil. Steril.75, 1234-1235. 10.1016/S0015-0282(01)01796-411384659
  182. C. R. Wira and J. V. Fahey (2008). A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS22, 1909-1917. 10.1097/QAD.0b013e3283060ea418784454
  183. C. R. Wira, J. V. Fahey, C. L. Sentman, P. A. Pioli and L. Shen (2005). Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol. Rev.206, 306-335. 10.1111/j.0105-2896.2005.00287.x16048557
  184. C. R. Wira, M. Ghosh, J. M. Smith, L. Shen, R. I. Connor, P. Sundstrom, G. M. Frechette, E. T. Hill and J. V. Fahey (2011). Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus. Mucosal Immunol.4, 335-342. 10.1038/mi.2010.7221048705
  185. C. R. Wira, M. Rodriguez-Garcia, Z. Shen, M. Patel and J. V. Fahey (2014). The role of sex hormones and the tissue environment in immune protection against HIV in the female reproductive tract. Am. J. Reprod. Immunol.72, 171-181. 10.1111/aji.1223524661500
  186. C. R. Wira, M. Rodriguez-Garcia and M. V. Patel (2015). The role of sex hormones in immune protection of the female reproductive tract. Nat. Rev. Immunol.15, 217-230. 10.1038/nri381925743222
  187. M. W. Woods, M. A. Zahoor, S. Dizzell, C. P. Verschoor and C. Kaushic (2018). Medroxyprogesterone acetate-treated human, primary endometrial epithelial cells reveal unique gene expression signature linked to innate immunity and HIV-1 susceptibility. Am. J. Reprod. Immunol.79, e12781-e1278110.1111/aji.12781
  188. F. Xiu, V. C. Anipindi, P. V. Nguyen, J. Boudreau, H. Liang, Y. Wan, D. P. Snider and C. Kaushic (2016). High Physiological concentrations of progesterone reverse estradiol-mediated changes in differentiation and functions of bone marrow derived dendritic cells. PLoS ONE11, e015330410.1371/journal.pone.015330427064901
  189. X. Zhou, C. J. Brown, Z. Abdo, C. C. Davis, M. A. Hansmann, P. Joyce, J. A. Foster and L. J. Forney (2007). Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women. ISME J.1, 121-133. 10.1038/ismej.2007.1218043622
  190. J. Z. Zhou, S. S. Way and K. Chen (2018). Immunology of the uterine and vaginal mucosae. Trends Immunol.39, 302-314. 10.1016/j.it.2018.01.00729433961
  191. J. Zhu, F. Hladik, A. Woodward, A. Klock, T. Peng, C. Johnston, M. Remington, A. Magaret, D. M. Koelle, A. Waldet al. (2009). Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat. Med.15, 886-892. 10.1038/nm.200619648930
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6177003/fullTextXML. The license for the article is Creative Commons Attribution. The main subject has been identified as human immunodeficiency virus infectious disease.